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Thesis Abstract 
The benefits of fish oil supplementation for inflammation based disorders has been well-
documented,[1] prompting investigations into the pathways through which these benefits are 
achieved.  This led Serhan et al. to the discovery of a new class of pro-resolution lipid 
mediators, termed ‘resolvins’.[2][3]  There has subsequently been much research into their being 
a potential treatment for chronic inflammatory diseases such as asthma,[4] diabetes,[5] and 
arthritis.[6]  The aim of this research was to study the bioactivity of resolvin E1 (RvE1) and its 
analogues; to do this a flexible and versatile route towards the chemical synthesis of RvE1 had 
to be developed, which would allow for easy modification of the stereochemistry of the C-C 
double bonds and hydroxyl groups, as well as producing fragments containing key functional 
groups.   
The first proposed route synthesised RvE1 from two key fragments termed the lactone and 
epoxide fragments.  RvE1 contains three stereogenic hydroxyl groups, one with S configuration 
and two with R configuration.  The epoxide fragment was to be converted into two adjacent 
sections of the RvE1 chain.  The S-stereocentre was introduced via hydrolytic kinetic resolution 
using a Jacobsen’s catalyst.[7]  The two R-stereocentres were introduced via the chiral pool 
originating from 1,2:5,6-di-O-isopropylidene-D-mannitol.  Unfortunately, problems were 
encountered late on in the synthesis of both fragments and therefore a new synthetic route had 
to be devised.   
The second proposed route synthesised RvE1 from two key fragments termed the alkyne and 
halide fragments.  The S-stereocentre and one R-stereocentre were proposed to be introduced 
via asymmetric reduction of a ketone group.  The other R-stereocentre was proposed to be 
synthesised with the use of chiral additives during an indium-mediated coupling reaction.[8]   
As work progressed on the halide fragment, the Lewis acid catalysed thermodynamic 
conversion of a branched chain homoallylic alcohol to its linear counterpart was trialled in 
order to obtain one of the conjugated diene system in RvE1.  Using literature conditions for a 
similar system[9] this reaction was unsuccessful.  The reaction mechanism was studied and a 
hypothesis was put forward that adding a catalytic amount of the aldehyde that the branched 
chain homoallylic alcohol was synthesised from to the reaction mixture would promote the 
thermodynamic conversion to the linear chain.  These conditions were trialled on a number of 
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different starting materials, leading to either an improvement in yield for the thermodynamic 
conversion, or the success of a previously unsuccessful conversion.   
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1.0 Resolvins: an Introduction 
1.1 Inflammation 
When the body’s defence system is compromised, whether it be from physical injury or 
invading pathogens, various mechanisms are set in motion to return the body back to its normal 
state.  The inflammatory response is one such mechanism, characterised by an increase in blood 
flow to the area of the problem.  This causes swelling and an increase in temperature which 
can lead to redness and pain.  The inflammatory response consists of the release of pro-
inflammatory mediators, and when the problem has been resolved this is followed by a 
resolution phase where the system is returned to normal.  Mast cells found in the tissues respond 
to the stimuli, whether it be pathogenic or physical, and release inflammatory mediators at the 
site.  These act to either recruit other active pro-inflammatory mediators found in white blood 
cells, such as neutrophils, or to activate the new cells that are being recruited. 
Acute inflammation is a vital component of the healing process.  It promotes healing by 
isolating the area affected and directing the cells necessary for healing towards it.  Chronic 
inflammation is an underlying disorder in a wide range of diseases including asthma, diabetes, 
rheumatoid arthritis and cardiovascular disease.  It is characterised by the body’s inability to 
correctly assess the appropriate response to certain stimuli, or an inappropriate stimulus 
triggering a response.  The latter is the case in asthma where common airborne particles can 
cause serious asthmatic attacks.  Chronic inflammation can also be the result of a failure of the 
body to initiate the resolution phase.  If chronic inflammation persists not only will the patient 
be in constant pain, but also the accumulation of potentially harmful inflammatory molecules, 
such as reactive oxygen species (ROS) and reactive nitrogen species (RNS), can lead to 
permanent tissue damage.[10] 
Current treatments of chronic inflammation include steroids, such as corticosteroids, or 
nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen.  Most of these act to reduce 
the production or action of the pro-inflammatory mediators, however recently the prospect of 
using treatments that focus on the resolution of inflammation have been considered as potential 
alternatives.[11]  
2 
 
1.2 The Discovery of Resolvins 
Research into the effects that fish oils have on human health spans back decades.  In 1980, an 
epidemiological study was conducted comparing the health of Greenland Inuits to a matched 
control group of Danes.[12]  The results showed that the natives of Greenland had a lower 
incidence of inflammation-based diseases, such as diabetes, asthma and myocardial infarction, 
than their Danish counterparts.  The Inuit diet contained a much larger amount of fish than the 
average European diet; fish is a high source of ω-3 polyunsaturated fatty acids (PUFAs) 
whereas poultry and eggs are a high source of ω-6 PUFAs.  PUFAs are fatty acids that contain 
more than one C-C double bond in their backbone.  The carboxylic acid end of the backbone 
is deemed the beginning of the chain and therefore the carbon adjacent to the carboxylic acid 
is termed the alpha carbon.  The opposite end of the backbone is deemed the end of the chain 
and therefore this methyl carbon is termed the omega carbon.  PUFA nomenclature is 
determined by the location of the first C-C double bond from the omega end; ω-3 PUFAs have 
their first C-C double bond between the 3rd and 4th carbon from the omega end, and ω-6 PUFAs 
have their first C-C double bond between the 6th and 7th carbon from the omega end.  Figure 1 
shows the structure of α-linolenic acid (ω-3 PUFA, 1), and linoleic acid (ω-6 PUFA, 2). 
 
 
Figure 1. The structures of α-linolenic acid (an ω-3 PUFA) and linoleic acid (an ω-6 PUFA), highlighting the 
location of the first C-C double bond from the omega end of the fatty acid backbone. 
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The average European diet contains roughly 10-20 times more ω-6 PUFAs than ω-3 PUFAs 
and in extreme cases (mostly seen in North America), this imbalance can extend to as much as 
30:1 in favour of ω-6 PUFAs.  As a result of the Inuits increased fish consumption, their intake 
of ω-3 and ω-6 PUFAs is reasonably balanced, compared with the European diet which is 
greatly skewed in favour of ω-6 PUFAs.[13]  The results of this research suggest that the 
consumption of fish, and therefore an increased intake of ω-3 PUFAs, offers some protection 
from inflammation associated diseases.  These findings have been echoed since relating to 
various inflammatory based diseases.[14],[15],[16] 
Much research into fish oil supplementation has since been completed.  It has been determined 
that the ω-3 PUFAs eicosapentaenoic acid (EPA) (3, Figure 2) and docosahexaenoic acid 
(DHA) (4, Figure 2) are the active components of fish oil in terms of their beneficial health 
effects.   
 
 
Figure 2. The chemical structures of EPA (ω-3 PUFA), DHA (ω-3 PUFA) and AA (ω-6 PUFA). 
 
EPA and DHA work by competing with arachidonic acid (AA) (6, Figure 2) for the 
cyclooxygenase (COX) and lipoxygenase (LO) enzymes.  These enzymes metabolise AA to 
the potent inflammatory mediator’s prostaglandins (PGs) and leukotrienes (LTs).  PGs are a 20 
carbon unit with a 5-membered ring incorporated whereas LTs are distinguished as having a 
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conjugated triene unit as shown in Figure 4.  EPA and DHA are competitive substrates for the 
COX enzymes. EPA can also act as a substrate for the 5-LO enzyme, further inhibiting the 
actions of AA.[17]  Figure 3 shows the metabolites of AA and EPA when they are metabolised 
by these two enzymes. 
 
 
Figure 3. Metabolites of EPA and AA from two key enzymatic pathways.[17] 
 
Thromboxanes (TXs) contain a 6-membered ether ring as shown in Figure 4.  The 2-series PGs 
and TXs derived from AA are much more potent inflammatory mediators than the 3-series 
equivalents produced by COX metabolism of EPA.  Likewise, the 4-series LTs are much more 
potent than their 5-series equivalents.  Due to the fact that ω-3 PUFAs are competitive 
substrates for these metabolising enzymes, fish oil supplementation should act to decrease the 
volume of potent pro-inflammatory mediators produced by the body. 
Recently it has come to light that these ω-3 PUFAs may have an active role in the resolution 
of inflammation, as well as the aforementioned decreasing of AA activity.   
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Figure 4. Examples of the structures of thromboxanes (TXs), prostaglandins (PGs) and leukotrienes (LTs). 
 
The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-
Prevenzione study investigated the effects of ω-3 PUFA and vitamin E supplementation on 
11,324 patients in Italy that had recently suffered a myocardial infarction.[1]  At the time, 
previous studies of the anti-inflammatory capabilities of both ω-3 PUFA and vitamin E had 
yielded conflicting results.  The participants were randomly assigned to roughly equal groups 
taking supplements of either just ω-3 PUFAs, just vitamin E, both ω-PUFAs and vitamin E, or 
a control group taking none.  It is interesting to note that the control group were not given a 
placebo pill to take, instead they simply took nothing.  This is unusual as a placebo helps to 
rule out any results that may be due to the ‘placebo effect’ rather that the beneficial effects of 
the programme.  The ‘placebo effect’ is a common phenomenon that occurs when patients 
believe that they are taking a substance beneficial to their health, and then begin to experience 
perceived or actual improvements to their condition.  It is a purely mental phenomenon but 
usually important to drugs trials as it helps to identify any improvements that are specific to 
the drug.   
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The participants of the GISSI-Prevenzione study were instructed to carry on taking any other 
medications prescribed by their physicians.  The participants were monitored for incidences of 
illness, in particular those relating to the cardiovascular system, e.g. fatal and non-fatal 
incidences of myocardial infarction or stroke, over a period of 3-5 years. The results showed 
that those participants taking fish oil supplements showed a statistically significant decrease in 
incidences of myocardial infarction and stroke.  When compared to the control group, the fish 
oil group had a 20% less chance of death from any cause, 30% less chance of cardiovascular 
death, and 45% less chance of sudden death.  The vitamin E group showed no statistical 
differences from the control group.  The GISSI-Prevenzione research group attributed the 
beneficial results found in this study to the ingestion of the fish oil supplement, however when 
the results were reviewed it was noted that most of the participants were also taking aspirin, as 
prescribed by their physician, alongside the fish oil supplementation.  This was not taken into 
account when statistically analysing the results, therefore it is not known what, if any, affect 
the additional aspirin had on the results. 
Serhan et al. investigated this possible benefit of a combination of fish oils and aspirin on 
inflammation.[2][3]  The group investigated their hypothesis that aspirin may be involved in the 
transformation of ω-3 PUFAs to novel bioactive mediators.  A murine model was used to 
monitor the production of compounds in inflammatory exudates in dorsal pouches.  
Inflammation was induced by injection of tumour necrosis factor (TNF)-α which is a cytokine 
(signalling molecule) involved in the initiation of systemic inflammation.  The murine diet was 
supplemented ω-3 PUFAs (EPA and DHA) to their normal diet and injected with aspirin as 
each test was carried out.  LC/MS/MS was used to analyse the inflammatory exudates and 
several novel compounds were detected.  Figure 5 shows the compounds detected when the 
mice had been supplemented EPA, whereas Figure 6 shows the compounds detected when they 
were supplemented with DHA.   
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Figure 5. Novel EPA derivatives found by LC/MS/MS analysis of inflammatory exudates.[2] 
 
 
Figure 6. Novel DHA derivatives found by LC/MS/MS analysis of inflammatory exudates.[3] 
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It was also noted that when these inflammatory exudates were injected intravenously into 
murine tissue, Polymorphonuclear cells (PMN) migration was reduced by approximately 60% 
which made them of great interest to their research.  PMN’s are a category of white blood cells 
that are called to the area of inflammation to attack or remove the invading pathogen.  During 
chronic inflammation they can attack healthy tissue and therefore the decrease in PMN 
migration shown here is a promising result. 
The group then moved on to investigate whether these same novel compounds would be found 
if human cells were treated in the same manner.  Endothelial cells were used as they express 
COX-2 enzymes that ω-3 PUFAs are a known substrate for.  The cells were treated with either 
EPA or DHA, and aspirin, as with the murine model, and then analysed by LC/MS/MS.  The 
results showed that 18R-HEPE (9, Figure 5), 18-HEPE (hydroxy-eicosapentaenoic acid), 15R-
HEPE, 15-HEPE and 17R-HDHA (hydroxy-docosahexaenoic acid) (12, Figure 6) were 
produced, implicating aspirin acetylated cyclooxygenase (COX)-2 as the enzymatic pathway 
towards their production.  When DHA was metabolised by COX-2 without the presence of 
aspirin, LC/MS/MS data confirmed that only 13-HDHA (17, Figure 7) was produced which 
was not observed when aspirin is present.  This suggests that the presence of aspirin is causing 
an alteration to the COX-2 enzyme allowing it to behave differently. 
 
  
Figure 7. The structure of 13-HDHA, a metabolite of DHA in the presence of COX-2.[3] 
 
It was found that aspirin has its effect on the metabolism of ω-3 PUFAs by acetylating the 
serine residue in the active site of the COX-2 enzyme. Figure 8 shows the structures of aspirin 
(19, Figure 8) and the amino acid serine (18, Figure 8).  Active sites of enzymes are very 
structure specific, and this slight change causes COX-2 to alter its metabolism of ω-3 PUFAs 
allowing for the production of these novel anti-inflammatory mediators. 
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Figure 8. The chemical structures of serine and aspirin. 
 
The exact method by which aspirin acetylation affects the action of the COX-2 enzyme has 
been the subject of great interest.  In 2013, Tosco proposed a mechanistic hypothesis which 
was supported by a computational method in order to explain the alteration in enzyme action.[18]  
According to this hypothesis, the configuration of the oxygenation of PUFAs by the COX-2 
enzyme is determined by the ability of the PUFA to conform in space so that the reactive part 
of the molecule is susceptible to oxygen attack, which in turn is determined by the amount of 
steric shielding produced by the rest of the enzyme active site.  The serine residue that becomes 
acetylated by aspirin is the Ser530 residue which means that it is the 530th amino acid in the 
peptide chain.  Figure 9 shows the proposed mechanism by which Ser530 is acetylated by 
aspirin.  The presence of the Tyr384 residue is a key component of this mechanism as its 
position in the enzyme active site allows it to hydrogen bond with the aspirin molecule, thereby 
polarising the carbonyl bond and allowing the acetylation to take place. 
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Figure 9. The proposed mechanism for the acetylation of Ser530 of the COX-2 enzyme by aspirin.[18] 
 
Tosco’s computational hypothesis shows that the acetylation of Ser530 causes the 
conformation of the PUFA to change sufficiently to prevent the formation of the cyclic 
endoperoxide intermediate on one side of the carbon chain.  On the other side of the carbon 
chain, the steric shielding provided by the Tyr385 residue shown in Figure 9 ensures that the 
oxygen can only attack from one face and therefore reverses the configuration of that 
stereogenic centre.  It also presents other C-C double bonds for oxygenation that weren’t 
accessible previously. 
After their discovery of the novel compounds produced by aspirin acetylated COX-2 enzymes, 
the Serhan group began to investigate their bioactivities.  In order for inflammation to persist, 
cells have to interact with other cells in order to recruit more inflammatory mediators.  18R-
HEPE (9, Figure 5) and 5,12,18-tri-HEPE (11, Figure 5) were isolated and tested in terms of 
their effects on migration of mediators from human PMN cells.  Both compounds inhibited 
PMN migration with the tri-hydroxy analogue doing so with the most potency.  It was found 
that these compounds inhibited LTB4 stimulated migration, and therefore the relevant G 
protein-coupled receptors were cloned and subjected to competition binding experiments.  18R-
HEPE (9, Figure 5) was found to be ineffective, while 5,12,18R-HEPE (11, Figure 5) was found 
to compete with LTB4 for the receptor site with an IC50 (half maximal inhibitory concentration) 
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of approximately 0.5 μM which is equivalent to that of LTB4 antagonists currently available 
on the market.  The results of this research suggest a possible mechanism for the anti-
inflammatory properties shown here by EPA (Figure 10). 
 
 
Figure 10. The mechanism of ω-3 PUFA activation suggested by Serhan et al.[2] 
 
The pathway shown earlier in Figure 3 suggests that EPA exhibits anti-inflammatory properties 
by being metabolised to less potent anti-inflammatory mediators than those produced if AA 
were the substrate.  When aspirin is present in the system, the COX-2 enzyme becomes 
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acetylated and allows the pathway shown in Figure 10 to become active.  This allows EPA to 
also exhibit anti-inflammatory properties by its ability to be metabolised into biologically 
active compounds.  These compounds have been shown to actively resolve inflammation, and 
complement the actions of the less potent inflammatory mediators produced in Figure 3.  This 
implies that EPA (and other ω-3 PUFAs such as DHA) could be an effective anti-inflammatory 
treatment as it targets the reduction of inflammation via two different metabolic pathways. 
The Serhan group coined the term ‘Resolvins’ as a name for these novel metabolites of ω-3 
PUFAs, the name coming from their description of being resolution phase interaction products.  
By definition they are “endogenously generated within the inflammatory resolution phase and 
downregulate leukocytic exudate cell numbers to prepare for orderly and timely resolution”.[3]  
The resolvins metabolised from EPA are termed E series resolvins and likewise resolvins 
metabolised from DHA are termed D series resolvins.  They conclude that their discovery may 
provide potential developments in the treatment and/or management of several diseases with 
underlying inflammatory problems. 
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1.3 Application of Resolvins 
In 2008, Mickleborough et al. compared EPA and DHA in terms of their potency for resolving 
inflammation.[19]  They used inflammation induced alveolar macrophages as the cell line and 
treated them with either EPA or DHA.  The results were analysed in terms of the presence of 
several pro-inflammatory mediators such as TNF-α and LTB4.  The results of the supernatant 
analysis showed that both EPA and DHA reduced the concentration of these mediators 
compared to a placebo, but EPA was significantly the more potent of the two.  This implies 
that E series resolvins are more effective in the resolution of inflammation than their D series 
equivalents. 
The preliminary results demonstrated by Serhan et al. showing the potential of resolvins in the 
resolution of inflammation[2],[3] prompted research into their possible application to the 
treatment of chronic inflammatory diseases.  Asthma is one such chronic inflammatory disease, 
where inflammation of the airways is a key aspect of the condition and therefore is a therapeutic 
target for its treatment.[20]  Table 1 shows the results of a selection of studies that have 
investigated the effects of resolvin E1 (RvE1) on airway inflammation using murine models.  
The authors in these papers state similar reasons for completing this research; they incorporate 
the determination of whether the beneficial effect that a diet rich in ω-3 PUFAs has on asthma 
prevalence is due to the presence and activity of resolvins, and whether the pro-resolution 
activity shown by RvE1 in other models can be transferred to a disease state such as asthma. 
The resolution interval (Ri) is a measure of how quickly inflammation is resolved.  It is 
determined by the period of time that it takes for inflammatory cell numbers to return to an 
acceptable (normal) level.  In the case reported in Table 1 by Haworth et al. it was determined 
by the number of eosinophils, macrophages and lymphocytes present in the BAL fluid.  As the 
Ri for RvE1 was found to be half that of unaided resolution (vehicle) it is clear that the addition 
of RvE1 is having an active resolving effect on airway inflammation.[21] 
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Table 1. A comparison of research into the effects of RvE1 on a murine model of asthma. 
Authors Year Results Ref. 
Aoki et al. 2007 In response to ovalbumin (OVA) challenge after RvE1 
injection compared to vehicle: 
 whole body plethysmography showed significantly 
reduced airway hyperresponsiveness (AHR) 
 significant reduction in eosinophil and lymphocyte 
recruitment in bronchoalveolar lavage (BAL) fluid 
 reduced mucus secretion 
[4] 
Haworth 
et al. 
2008 In response to OVA challenge after RvE1 injection compared 
to vehicle: 
 significant reduction in eosinophil and lymphocyte 
recruitment in BAL fluid 
 Ri for vehicle ~ 5 days.  Ri for RvE1 ~ 2.5 days 
 reduced mucus secretion 
 significant reduction in interleukin (IL)-17, IL-23, IL-6 
and IL-27 determined by enzyme-linked immunosorbent 
assay (ELISA) plates 
 significant increase in interferon (IFN)-γ determined by 
ELISA plates 
[21] 
Aoki et al. 2010 Followed up earlier research with investigation into the 
mechanism through which RvE1 exerts its effects on an 
asthma model.  RvE1 was injected at OVA sensitisation, OVA 
challenge, or both, and compared to vehicle. 
 significant reduction of AHR in all phases 
 significant reduction of eosinophil and lymphocyte 
recruitment in BAL fluid in all phases 
 significant reduction of goblet cell mucus secretion in all 
phases, however mice treated with RvE1 in both phases 
had most marked reduction 
 significant reduction in IL-4, IL-5 and IL-13 in all phases 
[22] 
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Eosinophils and lymphocytes are important in the pathogenesis of asthma as they are 
responsible for the recruitment of many pro-inflammatory mediators and cytokines that 
produce detrimental airway inflammation.  Interleukins are one such class of mediator that 
promote the production of T cells which are a cause of inflammation.  The fact that all three 
studies outlined in Table 1 show that RvE1 decreased the numbers of these cells is very 
important in terms of managing the condition.[4],[21],[22] 
Another problematic aspect of the asthmatic condition, as well as chronic inflammation, is 
excess mucus secretion by goblet cells in the lower airways.  The interleukins found in the 
airway not only contribute towards asthma by their relationship with inflammation, but they 
also stimulate the goblet cells to produce mucus.  The fact that RvE1 has been shown to not 
only reduce inflammation but also reduce numbers of key airway interleukins[21] and therefore 
reduce goblet cell secretion of mucus[4],[21],[22] indicates that it could be a very effective method 
of treatment as it targets multiple facets of the condition.  The investigation of Aoki et al. into 
the mechanism of action by RvE1 shows that it acts in multiple phases of resolution and 
therefore by multiple mechanisms.[22]   
A causal relationship between the decrease of ω-3 PUFAs in the modern western diet, and the 
increase in the incidence of diseases such as asthma has been suggested.[23]  This pattern is 
unlikely to be reversed, therefore even though more work is needed to determine the exact 
mechanisms of action, the preliminary results suggest that RvE1 could present a flexible 
therapeutic option due to it appearing to offer preventative actions, as well as aiding the 
resolution of inflammation.  
One of the major effects on airway inflammation that RvE1 has been shown to have is 
increasing macrophage function, and therefore increasing the removal of harmful pathogens in 
the lungs through phagocytosis.  Some compounds in cigarette smoke increase the production 
of ROS which in turn decrease macrophage function.  It has been shown that as little as 10 nM 
concentration of RvE1 can stop the production of these ROS and therefore stop any detrimental 
effects on macrophage function that would be incurred.[24]  This could have a huge impact on 
the treatment of certain chronic obstructive pulmonary disease (COPD) conditions where 
patients require good macrophage function to ensure a good quality of life. 
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Table 2. A summary of research into the effects of RvE1/PUFAs on inflammatory based diseases. 
Disease/Condition Results Ref. 
Dry Eye Dry eye is a multifactoral disease state caused by a lack of 
tear production which in turn causes inflammation of the 
cornea.  Animal models have shown that treatment with 
resolvins (both E and D series) increase tear production and 
as well as decrease the ocular inflammation.  A pilot study 
with human participants showed that after treatment with 
high-dose ω-3 PUFAs for 6 months, 100% of patients 
reported significant improvement in vision. 
[25],[26],[27] 
Cancer Chronic inflammation has recently been identified as key 
feature of tumorigenesis. Mice that have been genetically 
altered to endogenously produce higher levels of ω-3 
PUFAs were shown to exhibit a decrease in tumorigenesis.  
[28],[29] 
Multiple Sclerosis The ROS responsible for neuronal damage in multiple 
sclerosis are produced in excess by inflammatory 
mediators.  It is hypothesised that this inflammation is 
caused by a failure of the resolution system and therefore 
resolvins could be a novel therapeutic option. 
[30] 
Obesity related 
diseases 
Obesity is a catalyst for many chronic diseases due to 
continual inflammation of the adipose tissue not allowing 
the body to return to homeostasis.  It is hypothesised that 
dietary supplementation with ω-3 PUFAs (which will be 
metabolised by the body to resolvins) will be a valuable 
preventative measure against diseases such as type 2 
diabetes and non-alcoholic fatty liver disease. 
[31],[32] 
Osteoporosis Obesity and osteoporosis have been shown to be linked on 
a whole-body to cellular level.  Research has shown that 
changes in diet to implement a higher ratio of ω-3 to ω-6 
[33] 
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PUFAs lowers the low-grade chronic inflammation that is 
a characteristic of osteoporosis and obesity and therefore 
alleviates some of the problems associated with both. 
Schizophrenia Excess production of pro-inflammatory cytokines cause 
neuronal damage which leads to the onset of schizophrenia.  
Not only are resolvins potent anti-inflammatory mediators 
but they have been shown to express neuroprotective 
properties.  This suggests that resolvins could be used to 
prevent and/or treat schizophrenia. 
[34] 
Intestinal 
inflammation 
Inflammatory lesions are key components of intestinal 
diseases such as Crohn’s disease.  Animal models testing 
the viability of ω-3 PUFAs have so far generated 
conflicting results due to dose size, type of intestinal 
inflammation, and ratio of ω-3 PUFAs received in the 
treatment, therefore more research is needed into their 
being a viable treatment option. 
[35] 
Diabetes mellitus Diabetics are at high risk of atherosclerosis due to sugar 
deposits in the blood vessels, high platelet aggregation is 
therefore dangerous as this could cause blood clots to form 
around these sugar deposits.  Aspirin has anti-aggregation 
affects; unfortunately many diabetics are insensitive to 
aspirin in this manner.  After a course of combined aspirin 
and fish oil supplementation, the majority of patients 
showed a decrease in platelet aggregation.  More 
remarkably, one week after the combined supplementation 
course began those patients that were originally insensitive 
to aspirin were now sensitive to it. 
[5] 
Arthritis Experimental models of arthritis have shown that resolvins 
displayed anti-inflammatory and analgesic properties.  
[6] 
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There are currently several clinical trials under way using 
resolvin analogues for the treatment of arthritis. 
 
There are several other inflammatory disease states for which resolvins are being investigated 
as a potential new therapeutic alternative as shown in Table 2.  Inflammatory pain is one such 
area common in many disease states with a growing amount of research into its treatment.  
Inflammatory pain is a feature of diseases such as arthritis and can be of significant detriment 
to the everyday life of patients.  The current treatment of inflammatory pain conditions is either 
COX enzyme inhibitors that aim to reduce the production of inflammatory mediators, or 
opioids that act as a painkiller.[36]  There are however problems associated with both these 
methods; COX inhibitors can be unselective and therefore cause problems elsewhere in the 
body, even those that are selective to the COX-2 enzyme can cause cardiovascular problems, 
and although opioids are an effective painkiller initially, the body eventually adapts and builds 
up a tolerance.   
RvE1 and resolvin D1 (RvD1) were studied in terms of their effects on the central and 
peripheral nervous system in a murine pain model.[37]  Both RvE1 and RvD1 were found to 
attenuate inflammatory pain, and the mechanism of action was found to be central through the 
G protein-coupled receptor ChemR23 in the spinal cord.  However, peripheral actions such as 
reduced swelling were also seen, which is important to note as it suggests that resolvins are 
working against several facets of inflammatory pain. 
An interesting finding of this study was that pain receptors not associated with inflammatory 
pain were not affected by the presence of resolvins in the system; the mice were still responsive 
to external painful stimuli whilst the inflammatory pain was subdued.  Due to their specific 
action towards ‘chronic pain’, resolvins have also been suggested as a treatment for 
postoperative pain too.[38]  This theory has later been adapted into the suggestion of 
modification of patients pre and postoperative diets to include sources rich in ω-3 PUFAs to 
improve recovery.[39]  
The research discussed suggests that resolvins could be natural pharmacophores for the 
treatment of illnesses relating to chronic inflammation.[11],[40]  Treatments based on compounds 
already existing in nature have a high success rate in the pharmaceutical industry, largely due 
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to the fact that the molecule is already able to fit the appropriate receptors and pass the relevant 
cell boundaries.[41]  Although a possible problem can occur when the compounds are naturally 
available, as the body already has pathways in place to remove them and therefore they have a 
much more limited time of action before they are metabolised to inactive compounds.  In this 
case modifications have to be made in order to slow down these pathways allowing the drug 
more time in the body.   
Current treatments for inflammation mainly focus on blocking the production and expression 
of pro-inflammatory mediators, however many have been shown to have undesirable side-
effects.  Steroids have many known detrimental side-effects such as compromised wound 
healing and the onset of osteoporosis.[42]  Also COX-2 inhibitors have been linked with an 
increased risk of thrombosis,[42] and complications have also been noted with TNF-α-
neutralising therapy.[43]  As resolvins target the resolution phase of inflammation, it is not 
unrealistic to suppose that this different mode of action would allay the negative side-effects 
displayed by current inflammatory treatments.  Therefore, if resolvins or resolvin-based drugs 
were developed this could open up a new generation of therapeutic options available for 
patients.[44]  Resolvyx Pharmaceuticals are conducting clinical studies using RvE1 and a 
synthetic analogue to treat a variety of inflammatory-based conditions including dry eye, 
asthma, inflammatory bowel diseases and cardiovascular diseases, with promising results being 
shown in early stage clinical trials.[44]  
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2.0 Total Synthesis of Resolvins 
The results of the investigations into the biological actions of resolvins has sparked interest in 
their being used as therapeutic agents.  However, there is very little available naturally, 
prompting research into their total synthesis.  Total synthesis allows for the manipulation of 
smaller molecules to introduce the necessary functional groups and correct stereochemistry to 
the backbone of a larger molecule, such as RvE1. 
 
2.1 Total Synthesis of Resolvin E1 
To date there have been two published total syntheses of RvE1.  RvE1 has three stereogenic 
centres, two with R configuration and one with S configuration. 
Ogawa and Kobayashi, 2009, published the first total synthesis of RvE1.[45]  In their 
introduction they noted the clinical importance of RvE1 and how little is available from natural 
sources, hence their desire to chemically synthesise it.  In 1990, Kobayashi published a route 
towards the synthesis of LTB4 and when comparing the structure of RvE1 to that of LTB4 
(Figure 11), the similarities in the structures allowed them to deduce that synthetic strategies 
previously developed for the production of LTB4 could be applied to RvE1. 
 
 
Figure 11. Structures of RvE1 and LTB4. 
 
Scheme 1 shows the retrosynthetic route towards RvE1 that Ogawa and Kobayashi developed.  
The preparation of the vinyl borane 28 (Scheme 1) was not discussed in detail in this paper.  It 
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was only mentioned that the corresponding acetylene was subjected to hydroboration to yield 
the disiamylborane group.   
 
 
Scheme 1. Ogawa and Kobayashi retrosynthetic route towards RvE1. 
 
The R-stereocentre of 30 was introduced via asymmetric reduction of ketone 32 using a Noyori 
catalyst (Scheme 2), and resulted in 86% yield and > 98% ee. 
 
 
Scheme 2. Asymmetric reduction conditions used by Ogawa and Kobayashi for the introduction of an R-
stereocentre. 
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The R-stereocentre of 31 was introduced by kinetic resolution of racemic 34 (Scheme 3).  
Ogawa and Kobayashi went on to use both fragments in the synthesis of 31 as detailed in 
Scheme 3.  
 
 
Scheme 3. Kinetic resolution conditions used by Ogawa and Kobayashi. 
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Suzuki-Miyaura coupling was chosen as the main method of coupling the synthetic 
intermediates (Scheme 4), which is reliable and widely used method, this probably being the 
main reason for selection in this synthesis.  Initially LiOH was used instead of NaOH, which 
gave the carboxylic acid as opposed to the methyl ester, but chromatographic purification of 
this carboxylic acid proved problematic.  The methyl ester produced by using NaOH proved 
much easier to isolate. 
 
 
Scheme 4. Suzuki-Miyaura coupling conditions used by Ogawa and Kobayashi to synthesise 42. 
 
The route that Ogawa and Kobayashi used achieved mostly good yields throughout.  They 
reported that the synthesised RvE1 had a stereochemical purity of 92% and attributed the slight 
loss of purity to a possible instability of the conjugated double bond unit, but believed that they 
had achieved adequate purity for their molecule to be subjected to biological testing.  The fact 
that 100% stereochemical purity could not be obtained may be an area for concern, but 92% 
was still high enough to render the synthesis a success. 
In 2011, Allard et al. also published a synthetic route towards RvE1 citing their influence to be 
the growing research into the use of RvE1 as a new anti-inflammatory treatment.[46]  The 
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retrosynthetic route that the group followed is outlined in Scheme 5.  Parallels can be drawn 
between this route and the one devised by Ogawa and Kobayashi (Scheme 1); both groups used 
palladium coupling to combine together key fragments, albeit Ogawa and Kobayashi used 
Suzuki-Miyaura coupling whereas Allard et al. favoured Sonogashira coupling.  Also, a Wittig 
coupling is used to create some C-C double bonds in both routes. 
 
 
Scheme 5. Allard et al. retrosynthetic approach towards RvE1. 
 
The main difference between Ogawa and Kobayashi’s method and the Allard group method 
was the way that stereogenic centres are introduced into the molecule.  As previously stated, 
Ogawa and Kobayashi used asymmetric reduction and kinetic resolution of a racemic starting 
material to introduce their stereochemistry; Allard et al. used an asymmetric reduction to 
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achieve the S-stereocentre (Scheme 6), however the two R-stereocentres are introduced via the 
chiral pool, originating from (S)-glycidol (48, Scheme 5).  For the asymmetric reduction, Allard 
et al. also used a Noyori catalyst, drawing parallels with the Ogawa and Kobayashi route. 
 
 
Scheme 6. Asymmetric reduction conditions used by Allard et al. for the introduction of an S-stereocentre. 
 
The final coupling steps used Sonogashira conditions as outlined in Scheme 7 and Scheme 8.  
They achieved moderate yields of 50% and 68% respectively.  In each case, the terminal halide 
was created by Takai olefination.   
 
 
Scheme 7. Sonogashira coupling conditions used by Allard et al. for the first fragment coupling step in their 
synthesis of RvE1. 
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Scheme 8. Sonogashira coupling conditions used by Allard et al. for the final fragment coupling step in their 
synthesis of RvE1. 
Allard et al. concluded by stating that “further route modifications have allowed the large scale 
preparation of RvE1 for preclinical development activities and subsequent First in Man 
testing.”[46]  They didn’t however state what those modifications were, or what they deemed to 
be “large scale”. 
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2.2 Total Synthesis of other E Series Resolvins 
Resolvin E2 (RvE2) is another metabolite of EPA that has been identified as a synthetic target 
in this field.  As seen in Figure 12, RvE2 has two stereogenic centres, one with S configuration 
and one with R configuration.   
 
 
Figure 12. Resolvin E2. 
 
The first published synthetic route towards RvE2 was published by Inoue et al. in 2009.[47]  
This paper described a synthetic route towards RvE2 as well as an evaluation of its bioactivity.  
They stated that the potential of resolvins as an anti-inflammatory treatment was the motivation 
behind their research.  The retrosynthetic route that the group devised is outlined in Scheme 9. 
 
28 
 
 
Scheme 9. Inoue et al. retrosynthetic route towards RvE2. 
 
The group noted that there was an aspect of symmetry to the structure of RvE2 and came to the 
conclusion that the same chemistry could be used to synthesise these portions of the structure.  
The desymmetrisation of anhydride 58 produced (-)-57 and (+)-57 (Scheme 10) from which 
the pseudo-enantiomeric 55 and 56 were made. 
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Scheme 10. Conditions used by Inoue et al. for the desymmetrisation of anhydride 58. 
 
 
Figure 13. Quinine derivative used by Inoue et al. as the catalyst for the desymmetrisation of anhydride 58 
(Scheme 10). 
 
These stereoisomers were used to introduce the two stereogenic centres in the molecule.  Both 
were introduced by stereoselective alkylation through the use of metal chelation with the 
carbonyl group (Scheme 11 and Scheme 12).  This afforded good, but not perfect, 
30 
 
diastereoselectivity of 6:1 (Scheme 11) and 7:1 (Scheme 12) of preferred isomer to unpreferred, 
with reasonable yields.   
 
 
Scheme 11. Conditions used by Inoue et al. to S-stereocentre in their synthesis of RvE2. 
 
 
Scheme 12. Conditions used be Inoue et al to introduce the R-stereocentre in their synthesis of RvE2. 
 
A unique aspect of this group’s work was that they also conducted biological testing of their 
synthetic RvE2.  Figure 14 shows the effect that RvE2 administration had on neutrophil and 
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cytokine production in an in vivo inflammation model.  As little as 100 ng of synthetic RvE2 
was enough to produce a substantial decrease in neutrophil count.  They report that the results 
found for a 1 µg dose of their synthetic RvE2 are comparable to those of a 10 µg dose of a 
current anti-inflammatory treatment (dexamethasone, a steroid), therefore highlighting the 
potency of RvE2 
 
 
Figure 14. Effects of synthetic RvE2 on the number of inflammatory cells produced.[47] 
 
Rodriguez and Spur, 2012, also published a synthetic route towards RvE2. [48]  This group had 
previously published synthetic routes towards many D series resolvins which will be discussed 
in the following chapter.  Scheme 13 shows their proposed retrosynthetic route towards RvE2. 
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Scheme 13. Rodriguez and Spur retrosynthetic route towards RvE2. 
 
The group used asymmetric Noyori transfer hydrogenation to create the two stereogenic centres 
of the molecule, motivated by recent reports that the reaction was suitable to be carried out in 
water.  This method is environmentally friendly due to the lack of organic solvents being used 
in the process, which is preferable if the final product is to be used in biological testing.  Both 
stereogenic centres were produced in >93% ee.  Scheme 14 shows the conditions used to create 
the S-stereocentre; CTABr is used as the phase transfer catalyst and sodium formate as the 
reducing agent.  The only difference in conditions when creating the R-stereocentre was the 
use of the R-Noyori catalyst opposed to the S-Noyori catalyst. 
 
 
Scheme 14. Asymmetric Noyori transfer hydrogenation conditions used by Rodriguez and Spur to create the S-
stereocentre in their synthesis of RvE2. 
 
33 
 
Sonogashira coupling was used to good effect to join together the final synthetic intermediates.  
Scheme 15 outlines the conditions used to couple together fragments 68 and 70.  The same 
conditions were used for the second coupling, after the removal of the TMS protecting group. 
 
 
Scheme 15. Sonogashira conditions used by Rodriguez and Spur in their synthesis of RvE2. 
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2.3 Total Synthesis of D Series Resolvins 
In 2004, Rodriguez and Spur began their research into the synthesis of resolvins by publishing 
a first total synthetic route to resolvin D2 (RvD2), a metabolite of DHA (Figure 15).[49]  They 
cited the research of Serhan[2],[3] and co-workers as the influence for their work and the 
importance of finding a synthetic route towards RvD2, as so little is available naturally for 
biological testing.  RvD2 contains three stereogenic centres, two have S configuration and one 
has R configuration.   
 
 
Figure 15. The structures of DHA (4) and one of its metabolites, Resolvin D2 (74). 
 
Scheme 16 shows the retrosynthetic plan that Rodriguez and Spur devised.  The group used 
various methods to create the C-C double bonds present in the molecule which include Takai 
olefination, Lindlar reduction and Wittig coupling.  Sonogashira coupling was used to couple 
together the final intermediates.   
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Scheme 16. Rodriguez and Spur retrosynthetic route towards RvD2. 
 
The proximity of the R- and S-stereocentres on adjacent carbon atoms to each other meant that 
they were able to be obtained through the chiral pool strategy originating from 2-deoxy-ᴅ-
ribose acetonide (78, Scheme 16). 
The other S-stereocentre was created by the hydrolytic kinetic resolution (HKR) of an epoxide 
which resulted in the desired S-80 with > 94% ee.  Epoxide R-81 (shown in Figure 16) was 
also produced during this HKR, but Rodriguez and Spur did not utilise it in any following steps 
in their synthesis of RvD2. 
 
 
Scheme 17. Hydrolytic kinetic resolution conditions used by Rodriguez and Spur to create one of the S-
stereocentres of RvD2. 
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Figure 16. Epoxide with R configuration also synthesised from the conditions shown in Scheme 17, but not 
used in the rest of the Rodriguez and Spur synthesis of RvD2. 
 
Rodriguez and Spur followed this publication of RvD2 with a total synthetic route towards 
resolvin D5 (RvD5) in 2005.[50]  RvD5 has two stereogenic centres, both with S configuration.  
Their aim for this research was the same as that for RvD2, in that they wished to synthesise 
RvD5 in order for it to undergo biological testing.  Figure 17 shows the structure of RvD5 and 
Scheme 18 shows the retrosynthetic plan that Rodriguez and Spur followed. 
 
 
Figure 17. Resolvin D5. 
 
 
Scheme 18. Rodriguez and Spur retrosynthetic route towards RvD5. 
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Rodriguez and Spur used much of the same chemistry as demonstrated in the previous synthesis 
of RvD2, using Lindlar reduction to create cis double bonds and Takai olefination to create 
trans double bonds, with subsequent Sonogashira coupling to join synthetic intermediates.  The 
similarities also extended to the stereogenic centres which were generated by hydrolytic kinetic 
resolution of a racemic epoxide (Scheme 19).  This produced the desired (+)-benzyl glycidyl 
ether ((+)-84) in 45% yield and in > 99% ee.  The conditions outlined in Scheme 19 would also 
have produced diol 88 (Figure 18), however as with their synthesis of RvD2, Rodriguez and 
Spur only utilised one of the products of the HKR in their following steps and thereby discarded 
50% of the reaction material produced by this reaction. 
 
 
Scheme 19. Hydrolytic kinetic resolution conditions used by Rodriguez and Spur to create (+)-benzyl glycidyl 
ether from which both S-stereocentres of RvD5 are synthesised. 
 
 
Figure 18. Diol with R configuration also synthesised from the conditions shown in Scheme 19, but not used in 
the rest of the Rodriguez and Spur synthesis of RvD5. 
 
Both stereogenic centres being of S-configuration allowed Rodriguez and Spur to use the 
product of this reaction, (+)-benzyl glycidyl ether (84, Scheme 19), to create both of them.  
Yamaguchi conditions were used in both instances to ring open the epoxide and extend the 
carbon chain; Scheme 20 shows the conditions used for one, the other uses 86 instead of 1-
butyne and results in 85% yield. 
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Scheme 20. Yamaguchi conditions used by Rodriguez and Spur to ring open the epoxide in their synthesis of 
RvD5. 
 
The group encountered problems with the final removal of protecting groups where the strong 
alkaline conditions required began to decompose the product.  In order to overcome this 
problem, the group used a natural lipase from a yeast cell to hydrolyse both benzoate groups 
and the methyl ester under mild conditions (pH 7.2), therefore giving the finished RvD5 
compound in 75% yield. 
Rodriguez and Spur also published the first total synthesis of resolvin D6 (RvD6) in 2012, 
seven years after they published their synthesis of RvD5.[51]  RvD6 has two stereogenic centres, 
both with S configuration as shown in Figure 19.  Their aim in completing this research is the 
same as for the syntheses of RvD2 and RvD5 in that they want to prepare RvD6 in order for 
further biological and pharmacological testing to be carried out on it.  Their retrosynthetic plan 
is outlined in Scheme 21. 
 
 
Figure 19. The chemical structure of resolvin D6. 
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Scheme 21. Rodriguez and Spur retrosynthetic route towards RvD6. 
 
This paper was published in the same year as their synthesis of RvE2 discussed earlier, and as 
a consequence similarities can be drawn in certain aspects of the synthetic routes.  For example, 
both used Noyori asymmetric transfer hydrogenation for the creation of stereogenic centres 
opposed to the HKR used in their earlier syntheses of RvD2 and RvD5.  When Rodriguez and 
Spur used HKR conditions in order to obtain stereogenic centres, they subsequently discarded 
50% of the material from the reaction by only taking forward one product; when using Noyori 
conditions they were able to synthesise solely their desired 95 with S-configuration in > 95% 
ee (Scheme 22). 
 
 
Scheme 22. Noyori asymmetric hydrogenation conditions used by Rodriguez and Spur to create an S-
stereocentre in their synthesis of RvD6. 
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The other stereogenic centre was produced by Sharpless asymmetric epoxidation.  This 
produced 97 with 98% ee (Scheme 23) and was subsequently ring opened to give the second 
S-stereocentre. 
 
 
Scheme 23. Sharpless asymmetric epoxidation conditions used by Rodriguez and Spur in their synthesis of 
RvD6. 
 
Later in 2012, Rodriguez and Spur published a total synthesis of RvD1,[52] the structure of 
which is shown in Figure 20.  RvD1 has three stereogenic centres, two with S configuration 
and one with R configuration.   
 
 
Figure 20. Resolvin D1. 
 
Scheme 24 shows the retrosynthetic pathway Rodriguez and Spur used to synthesise RvD1.  
The chemistry involved resembles that used in the group’s previous synthesis of RvD2 in 2004; 
the most striking similarity being the use of the same chiral pool starting material, 2-deoxy-ᴅ-
ribose acetonide (78), to introduce the stereogenic centres.  A Wittig reaction and Sonogashira 
coupling conditions were used to bring the fragments together. 
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Scheme 24. Rodriguez and Spur retrosynthetic route towards RvD1. 
 
Both RvD2 and RvD1 have three stereogenic centres with two of those on adjacent carbon 
atoms.  In their synthesis of RvD2, 2-deoxy-ᴅ-ribose acetonide was only used to produce these 
adjacent stereogenic centres.  However, the synthesis of RvD1 was adapted to use this chiral 
pool compound for all centres.   
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Scheme 25. The chiral pool compound used by Rodriguez and Spur to create the adjacent R- and S- 
stereocentres in their synthesis of RvD1. 
 
 
Scheme 26. The chiral pool compound used by Rodriguez and Spur to create the other S-stereocentre. 
 
How Rodriguez and Spur utilised 2-deoxy-ᴅ-ribose acetonide is outlined in Scheme 25 and 
Scheme 26.  For the S-stereocentre created in Scheme 26, manipulation was required in order 
to obtain the single hydroxyl group.  This was achieved by the addition of LDA to 106.  
However, the desired iodide 100 was only synthesised in 40% yield, with unwanted by-
products being formed also. 
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2.4 Conclusions 
The main conclusion that can be drawn from the previous syntheses of E series and D series 
resolvins is that the introduction of the stereogenic centres seems to be the most problematic 
issue.   
The chiral pool is an attractive method of stereocentre introduction, and does not lead to 
potential difficulty in enantiomer separation.  However, as the stereocentre is formed in the 
early stages of a total synthesis, there is potential for the stereocentre to be lost or inverted 
further along in the route depending on what chemistry is being used.  Therefore a high degree 
of planning may be necessary when using this method, to either avoid chemistry that may 
destroy the stereogenic centre, or if techniques that invert stereochemistry are to be used, to 
select the necessary configuration of the chiral pool to start with.  Rodriguez and Spur used the 
chiral pool in their synthesis of RvD1 in 2012 for all three of the stereogenic centres present; 
2-deoxy-ᴅ-ribose was the source from the chiral pool (Figure 21).[52]  The first reaction that 2-
deoxy-ᴅ-ribose acetonide was used in (Scheme 25) only yielded 43%, which is obviously low.  
The second yielded a higher 60% (Scheme 26).  However, further manipulation was necessary 
to leave only one hydroxyl group, and this reaction produced an unwanted side-product which 
resulted in 50% of the material produced being discarded.  Therefore, in this synthesis 
Rodriguez and Spur sacrifice a significant amount of yield in order to use this particular chiral 
pool compound. 
 
 
Figure 21. 2-Deoxy-ᴅ-ribose acetonide: the chiral pool compound used by Rodriguez and Spur, 2012. 
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Allard et al.’s 2009 synthesis of RvE1 also used chiral pool, this time for the introduction of 
two out of the three stereogenic centres present.[46]  (S)-Glycidol was used as the source from 
the chiral pool for both of these stereogenic centres (Figure 22).  The first reactions that (S)-
glycidol was used in produced the desired products in good 77% and 86% yields. 
 
 
Figure 22. (S)-Glycidol: the chiral pool compound used by Allard et al., 2009. 
 
Another method used for the introduction of stereogenic centres was hydrolytic kinetic 
resolution.  Kinetic resolution separates enantiomers in a racemic mixture by utilising the 
different reaction rates of each enantiomer in the presence of a chiral catalyst.  In the case of 
HKR the reaction in question is with water, and the chiral catalyst used is a Jacobsen’s catalyst.  
Rodriguez and Spur utilised the HKR of racemic epoxides in their 2004 synthesis of RvD2[49] 
(Scheme 17) and 2005 synthesis of RvD5[50] (Scheme 19), both times using the Jacobsen’s 
catalyst shown in Figure 23. 
 
 
Figure 23. (R,R)-salen-Co(III)-OAc: Jacobsen's catalyst used by Rodriguez and Spur for HKR. 
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This produced good ee’s, and as the reaction yields one enantiomer as an epoxide and the other 
as a diol, they are easy to separate.  However in both instances of Rodriguez and Spur using 
this method they only used one product/enantiomer in their synthesis.  This meant that at least 
50% of the material was discarded which is not efficient as a step in a long synthetic route.  
Therefore if HKR is to be used as a viable step in a synthesis, both enantiomers produced 
should be worked into the synthesis so as not to waste material. 
The other popular method for introducing stereogenic centres to resolvins is asymmetric 
reduction of a ketone to an alcohol.  This route was utilised in the synthesis of RvE1 by both 
the Ogawa and Kobayashi[45] (Scheme 2), and the Allard group[46] (Scheme 6), as well as by 
Rodriguez and Spur in their syntheses of RvE2[48] (Scheme 14) and RvD6[51] (Scheme 22). 
 
 
Figure 24. RuCl[(S,S)-TsDPEN](p-cymene): Noyori catalyst used to produce S-stereocentres by asymmetric 
reduction of ketones to alcohols. 
 
This again provided the desired enantiomer in high ee’s.  However, any trace amount of the 
undesired enantiomer can be difficult to separate from the mixture.  Also, the different groups 
had varying success with reaction yields, which ranged from 60-89%. 
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3.0 Aims 
The research outlined previously in chapter 1 shows the potential of resolvins as a therapeutic 
option for a number of inflammation-based diseases, such as asthma.  Due to the relatively 
limited natural availability of resolvins, there is an associated high cost of the parent 
compounds and their related fragments and building blocks.  Consequently there is a growing 
research focus on the chemical synthesis of these fish oil metabolites as outlined in chapter 2.  
RvE1 (Figure 25) has been shown to have the most potent anti-inflammatory properties of the 
newly discovered resolvin family,[19] and therefore will be the focus of this research.  
 
 
Figure 25. The chemical structure of Resolvin E1. 
 
All resolvin compounds have similar structures in that they are essentially a carboxylic acid 
that contains a series of C-C double bonds and stereogenic centres and hydroxy groups, yet as 
mentioned different members of the resolvin family exhibit different levels of bioactivity.[19]  
It is the intention of this research group to determine which aspects of the chemical structure 
of RvE1 are integral to its bioactivity.  This is proposed to be done by comparing the 
inflammatory cell count in cell cultures of inflammation-induced lung epithelial cells that have 
been treated with either RvE1 or other related analogues.  These related compounds are 
intended to be a series of modified analogues of RvE1 with changes to the stereochemistry of 
either the C-C double bonds or the hydroxyl groups.  It is also the intention to test key fragments 
of RvE1 to determine whether the whole structure plays a role or whether just specific 
functional groups.   
This research will allow for RvE1 (or its modified analogues) to be a much more viable drug 
candidate, as if it is found that the different stereochemistry of certain groups has no effect on 
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activity, then the synthesis towards a variety of stereoisomers becomes in theory a lot simpler.  
Also, the same logic applies if only a key fragment is producing the bioactivity. 
In order to do this, a flexible and versatile route towards the chemical synthesis of RvE1 needs 
to be developed, which allows for easy modification of the stereochemistry of the C-C double 
bonds and hydroxyl groups, as well as producing fragments containing key functional groups. 
RvE1 contains several challenging synthetic aspects owing to the presence of three stereogenic 
centres, a diene unit, and a triene unit, that previous groups have had varying success 
assembling.  Therefore, throughout this proposed total synthesis there will be avenues to 
expand existing, or develop new, methodology in order to tackle these challenging aspects. 
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4.0 Results and Discussion 
4.1 Initial Synthetic Route Towards RvE1 
There have already been two previously reported total syntheses of RvE1.  These were 
considered in the development of a novel retrosynthetic plan for this research project.  With 
this in mind, the retrosynthetic plan shown in Scheme 27 was developed and followed.  
The retrosynthetic plan splits the molecule into two key fragments that for ease of future 
discussion will be referred to as the epoxide fragment (109) and the lactone fragment (110) 
(Figure 26).  These can be modified and joined together before final deprotection to yield RvE1.   
 
 
Figure 26. The key epoxide and lactone fragments of the synthetic plan towards RvE1 outlined in Scheme 27. 
 
Although the retrosynthetic plan splits RvE1 into three fragments (112, 113, and 114, Scheme 
27), the epoxide fragment (109) is proposed to be used to create both 112 and 113.  Generating 
two key fragments from the same route allows for the number of steps in the synthesis to be 
limited. 
Both key fragments contain stereogenic centres, the S-stereocentre obtained from the lactone 
fragment and planned to be introduced via hydrolytic kinetic resolution, and the two R-
stereocentres obtained from the epoxide fragment and introduced via the chiral pool originating 
from 1,2:5,6-di-O-isopropylidene-D-mannitol (117, Scheme 27). 
49 
 
 
Scheme 27. Novel retrosynthetic plan for the synthesis of RvE1. 
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4.1.1 Synthesis of the RvE1 Lactone Fragment 
The initial synthetic plan to the lactone fragment was proposed to take 10 steps as shown in 
Scheme 28 and Scheme 29.  This plan was developed due to a close literature precedent already 
available for the hydrolytic kinetic resolution of the racemic epoxide (step d, Scheme 28).[53] 
 
 
Scheme 28. Proposed reagents and conditions: (a) NaOEt, 4-bromo-1-butene; (b) LiCl, DMSO, H2O; (c) 
mCPBA, CH2Cl2; (d) (R,R)-salen-Co(III)-OAc, H2O; (e) LiOH, THF, H2O; (f) CSA, CH2Cl2; (g) Amberlyst-15, 
4Å molecular sieves, MeCN. 
 
 
Scheme 29. Proposed reagents and conditions: (a) oxalyl chloride, CH2Cl2, DMSO, Et3N; (b) BrCH2PPh3Br, 
tBuOK, THF; (c) tBuOK, THF. 
 
This portion of the synthesis sees the introduction of a stereogenic centre (Scheme 28, step d) 
through hydrolytic kinetic resolution (HKR).  This creates epoxide 124 (Scheme 28) with R 
configuration and diol 123 (Scheme 28) with S configuration.  In lactone 118 (Scheme 28), the 
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stereogenic centre has S configuration, but as shown by steps e, f and g in Scheme 28, the diol 
123 (Scheme 28) is not wasted as both products of the HKR can be converted to desired lactone 
enantiomer 118 (Scheme 28).  This is a very valuable aspect of the synthetic plan as it ensures 
that no material is wasted by not being taken through to the next steps.  Lactone 118 (Scheme 
29) then undergoes functional group interconversion (FGI) as shown in Scheme 29, in order to 
give the desired key synthetic fragment 127 (Scheme 29). 
The first step in the synthesis of this lactone fragment is shown in Scheme 30, and corresponds 
to step a in Scheme 28.  The alkylation of diethyl malonate with 4-bromo-1-butene to produce 
121 (Scheme 30) proceeded smoothly and resulted in an excellent yield of 91%.   
 
 
Scheme 30. Alkylation of diethyl malonate to give 121. 
 
NaOEt was prepared in situ from sodium in ethanol before the addition of diethyl malonate. 
The reaction was carried out under an inert atmosphere of nitrogen.  Following deprotonation 
of diethyl malonate (30 min stirring), 4-bromo-1-butene was added and stirred overnight under 
reflux to yield the desired SN2 product.  
1H NMR spectroscopy was used to detect the presence 
of a ddt at 5.70 ppm and a multiplet at 5.00-4.92 ppm representing the protons of the C-C 
double bond, which was supported by the correct ion present in HRMS.  Bulb-to-bulb 
distillation was used to isolate 121 (Scheme 30).  The carbon-carbon double bond introduced 
at this point will undergo FGI later on in the synthesis in order to introduce one of the 
stereogenic centres. 
A Krapcho decarboxylation was chosen to convert diester 121 (Scheme 31) to ethyl                        
5-hexenoate (119, Scheme 31).  This is an attractive method of decarboxylation, as only one 
of the malonic ester groups is removed, leaving the other intact.  This is not the case with other 
alternative routes such as basic hydrolysis, where a subsequent reaction to regenerate the 
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alkylated ester is required.  Krapcho discovered that β-keto esters undergo decarboxylation 
when heated with aqueous DMSO,[54] and as the reagents required were cheap and readily 
available these conditions were trialled as shown in Scheme 31, and entry 1 of Table 3, page 
55.  An undistilled bottle of DMSO (4 eq) was used, with distilled water (2 eq) added. 
 
 
Scheme 31. Proposed Krapcho decarboxylation conditions to produce ester 117. 
 
These conditions however, produced no reaction.  Krapcho states that if an α-hydrogen is 
present in the β-keto ester, then water should be able to effect the decarboxylation at high 
temperatures.  However, if this does not work, or there are no α-hydrogens present, then a salt 
is required to effect decarboxylation.  He performed mechanistic studies by monitoring the 
production of reaction intermediates and proposed that the structure of the malonic ester 
dictates the method by which the salt affects decarboxylation.  He suggested that for 
disubstituted malonic esters the salt acts by attacking the R1 group of the ester, as shown in 
Scheme 32, whereas for monosubstituted esters the salt attacks the carbonyl group directly, as 
shown in Scheme 33.[54]   
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Scheme 32. Krapcho's proposed mechanism for the decarboxylation of disubstituted malonic esters in the 
presence of a salt.[55] 
 
 
Scheme 33. Krapcho's proposed mechanism for the decarboxylation of monosubstituted malonic esters in the 
presence of a salt.[55] 
 
Although 119 does contain an α-hydrogen, the presence of the alkyl chain may be effecting its 
reactivity, so NaCl was added to the reaction mixture (Table 3, entry 2).  A reaction did occur 
after this addition, evident by the disappearance of the triplet at 3.29ppm in the 1H NMR 
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spectrum; this triplet represented the proton on the 2 carbon of the malonate (121, Scheme 31), 
the chemical shift of which is markedly decreased by the removal of the neighbouring carbonyl.  
However, only trace yields (less than 5%) were obtained so clearly further optimisation was 
required. 
Firstly, it was hypothesised that the decarboxylation may be more successful on methyl esters 
than ethyl esters, due to the methyl group being more susceptible to the required SN2 attack by 
the chloride ion. 
 
 
Scheme 34. The alkylation of dimethyl malonate (135) to produce 136, which was then subjected to Krapcho 
decarboxylation to produce methyl 5-hexenoate (137). 
 
The dimethyl analogue 136 (Scheme 34) was synthesised and submitted to Krapcho conditions.  
However, this gave no improvement over the reaction of the diethyl analogue 121 (Scheme 
31). 
It was clear that further optimisation would be needed.  As the alkylation step for the diethyl 
analogue provided better yields than that of the dimethyl ester (91% compared to 82% 
respectively), the optimisation study was carried out on this (Table 3). 
The first parameter of the experiment that was changed was the reaction temperature.  At 190°C 
the reaction yielded little to no product (Table 3, entries 1-2).  Lowering the temperature to 
110°C was considered as the reaction still requires heat to work, and 110°C is above the boiling 
point of the added water but lower than that of DMSO.  However, this again yielded no reaction 
(Table 3, entry 3).   
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Table 3. Optimisation conditions for the Krapcho decarboxylation of 121 (Scheme 35) to give 119 (Scheme 35). 
Entry Salt Temperature 
(°C) 
Reaction 
Time (Hr) 
DMSO 
Source 
Yield (%) 
1 - 190 8 Undistilled - 
2 NaCl 190 8 Undistilled < 5% 
3 NaCl 110 8 Undistilled - 
4 NaCl 190 24 Undistilled 6% 
5 NaCl 190 48 Undistilled 13% 
6 NaCl 190 48 Anhydrous 30% 
7 LiCl 190 24 Anhydrous 43% 
8 LiCl 190 48 Anhydrous 80% 
9 LiCl 110 48 Anhydrous 18% 
 
The reaction temperature was returned back to reflux, and the next parameter that was 
investigated was the reaction time.  Initially this was 8 h, but was increased to 24 h and 48 h 
(Table 3, entries 4 and 5 respectively).  The yield did improve to a quantifiable 6% and 13% 
respectively (Table 3, entries 4 and 5 – the rest of the reaction material was returned starting 
material, 121), but this indicated that there was a more fundamental problem with the reaction 
yet to be discovered. 
The DMSO source was changed to anhydrous grade rather than undistilled (Table 3, entry 6).  
The original undistilled DMSO was suspected to have contained some contamination.  
Krapcho’s conditions require aqueous DMSO, but as distilled water was being added separately 
anyway, an anhydrous DMSO source was trialled with the theory that it would be ‘cleaner’ and 
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therefore remove the affect that contaminates might have had on the reaction.  This resulted in 
an increase in yield to 30% (Table 3, entry 6). 
 
 
Scheme 35. Optimised Krapcho decarboxylation conditions to produce ester 119 in 80% yield (entry 8,        
Table 3). 
 
The breakthrough came when the salt was changed from NaCl to LiCl, as LiCl is more soluble 
in polar organic solvents due to the smaller size of the Li+ ion.  This proved to be a great 
improvement, giving 80% yield after 48 h at reflux (Table 3, entry 8).  Again, lowering the 
temperature had a detrimental effect on the yield (Table 3, entry 9). 
An alternate approach to ethyl 5-hexenoate was attempted (Scheme 36).  This involved the 
oxidation of 5-hexen-1-ol (138, Scheme 36) to hex-5-enoic acid (139, Scheme 36) using 
pyridinium dichromate (PDC) as the oxidising agent.  It was planned that the carboxylic acid 
would then be converted into the ethyl ester in order to give the desired ethyl 5-hexenoate (119, 
Scheme 36), using Fischer esterification conditions.  The initial oxidation did prove to be 
successful, but given the breakthrough in the Krapcho decarboxylation, it was decided to 
continue with those conditions so as to avoid the use of undesirable chromium reagents used 
in Scheme 36. 
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Scheme 36. The proposed oxidation of 5-hexen-1-ol (138) to hex-5-enoic acid (139), and subsequent conversion 
to ethyl 5-hexenoate (119). 
 
In order to introduce the stereogenic centre as discussed earlier (Scheme 28), the terminal 
carbon-carbon double bond of ethyl 5-hexenoate is converted into an epoxide as shown in 
Scheme 37.  
 
 
Scheme 37. Epoxidation of ethyl 5-hexenoate (117) to give epoxide 120. 
 
The oxidising agent chosen for this conversion was mCPBA as there was already a literature 
precedent for the same substrate that showed good yields.[53]  The reaction proceeded as 
reported with a yield of 79% and generated the desired product as a yellow oil.  It was possible 
to visually monitor the progress of the reaction to an extent, as when the mCPBA had been 
reduced to meta-chlorobenzoic acid, a white precipitate was produced.  The best yields were 
obtained when the reaction was allowed to stir at room temperature overnight, and could be 
confirmed by 1H NMR spectroscopy of the crude product as the ddt at 5.79 ppm and multiplet 
58 
 
at 5.08-4.95 ppm, respectively, representing the protons of the C-C double bond shown in the 
ethyl 5-hexenoate (119) are absent. 
Hydrolytic kinetic resolution (HKR) was chosen to isolate the desired enantiomer of the 
racemic epoxide 122 (Scheme 37).[53]  As mentioned previously, in this particular case this 
method is very synthetically useful as both products can be taken forward in the retrosynthetic 
plan (Scheme 28).  An advantage of HKR is that no organic solvents are required as the reaction 
is carried out in water, which makes it an environmentally friendly method.   
HKR requires a class of catalyst termed Jacobsen’s catalysts in order to be enantiomerically 
selective.  HKR was developed by Jacobsen as a route towards enantiomerically pure terminal 
epoxides which are highly valuable in terms of chiral building blocks.  Prior to the development 
of this method, the ‘gold standard’ for producing enantiomerically pure epoxides was the 
Sharpless epoxidation (Jacobsen had previously worked in the Sharpless research group and 
this was no doubt where his interest in this area was piqued).  However, this method requires 
the presence of an allylic alcohol group.  Jacobsen pursued the investigation into synthesising 
enantiomerically pure terminal epoxides, without the need for the alcohol group required in the 
Sharpless method.  The salen ligand was investigated for this purpose as it was readily available 
in both enantiomeric forms.  Jacobsen determined that metal-salen complexes allowed for one 
enantiomer of an epoxide to be susceptible to ring-opening by water faster than the other, and 
therefore converted into a diol faster than the other enantiomer.  This allowed for the synthesis 
of an enantiomerically pure terminal epoxide and an enantiomerically pure diol, both of which 
were produced in high ee’s, and Jacobsen noted that the diol could also be a valuable chiral 
building block along with the epoxide. 
If an epoxide with S configuration is desired (and therefore a diol with R configuration), then 
the (S,S) Jacobsen’s catalyst is required.  Conversely, if an epoxide with R configuration is 
desired (and therefore a diol with S configuration), then the (R,R) Jacobsen’s catalyst is 
required.[7]  As mentioned earlier (Scheme 28) the R-epoxide and S-diol are required in this 
synthesis, therefore a Jacobsen’s catalyst with (R,R) configuration will be used.[56] 
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Scheme 38. Planned HKR of racemic epoxide 122. 
 
The catalyst chosen to attempt this resolution was (R,R)-salen-Co(III)-OTs (141, Scheme 39), 
as it was simple to prepare from (R,R)-salen-Co(II) (Scheme 39), with good yields promised in 
the literature.[57]  This was a fairly simple reaction in which (R,R)-salen-Co(II) and                         
p-toluenesulfonic acid monohydrate were stirred overnight in a vessel open to air.  The crude 
product was then suspended in hexane and the remaining solid was filtered, yielding                     
(R,R)-salen-Co(III)-OTs as a green solid in a nearly quantitative yield of 98%. 
 
 
Scheme 39. Preparation of (R,R)-salen-Co(III)-OTs (141). 
 
When the HKR was attempted with this catalyst, only starting material was recovered and 
therefore no resolution had taken place.  It is possible that the bulky tosyl group was hindering 
the cobalt coordination to the oxygen of the epoxide, and therefore a smaller ligand was trialled.   
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Scheme 40. Preparation of (R,R)-salen-Co(III)-OAc (143). 
 
(R,R)-Salen-Co(III)-OAc (143) was synthesised from Co(OAc)2 and the salen ligand 142 
(Scheme 40) in glacial acetic acid open to air.  When the excess glacial acetic acid was 
removed, the crude product was left as a brown solid which was purified by dissolving in 
methanol, with the subsequent dropwise addition of distilled water causing the product to 
precipitate.  Herein arose a slight difficulty as the product is a very fine powder which passed 
through most filter papers.  This was rectified by using a centrifuge to isolate the solid and this 
afforded a good yield of 88%.   
 
 
Scheme 41. HKR of 122 using (R,R)-salen-Co(III)-OAc to give R-124 and S-123. 
 
The resolution was attempted with (R,R)-salen-Co(III)-OAc and the reaction monitored by thin 
layer chromatography (TLC).  After stirring the mixture overnight, two compounds were 
identified in the reaction mixture through the use of TLC, one that corresponded to the original 
epoxide and a new, much more polar compound as well.   
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1H NMR spectroscopy was used to identify the two compounds as epoxide 124 (Scheme 41) 
and diol 123 (Scheme 41), with the diol being the much more polar compound as expected.  
Epoxide 124 (Scheme 41) was isolated in 45% yield, and diol 123 (Scheme 41) was isolated in 
19% yield.  The latter was slightly disappointing.   However, as the total yield of this reaction 
was a reasonable 64%, optimisation was not pursued at this point in time. 
Optical rotation analysis was carried out in order to determine whether they had been obtained 
with the correct stereochemical configuration.  Optical rotation analysis is a type of polarimetry 
which distinguishes between enantiomers based on their optical activity (the ability to rotate 
the plane of polarised light in opposite directions), the concentration of the sample solution, 
and also the path length of the cell.  Difference in the solvent used can also have an effect on 
the reading.  The R-epoxide 124 (Scheme 41) gave an optical rotation measurement of [α]𝟐𝟎
ᴅ
 = 
+15.8° (c 1.0, CHCl3), which agrees with the literature value of [α]
𝟐𝟎
ᴅ
 = +14.9° (c 0.2, 
CHCl3).
[53]  The S-diol 123 (Scheme 41) gave an optical rotation measurement of [α]𝟐𝟎
ᴅ
 = -18.0° 
(c 1.0, EtOH), which also agrees with the literature value of [α]𝟐𝟎
ᴅ
 = -14.1° (c 2.0, EtOH).[53]  
The enantiomeric excess of the products was determined by chiral HPLC; R-124 (Scheme 41) 
was produced in 98.2% ee and S-123 (Scheme 41) was produced in 81.6% e.e.  It was a little 
disappointing that the enantiomeric excess of the diol was below 90%, but the value produced 
is still good enough to proceed. 
After the configuration of the stereogenic centre had been determined, another functional group 
was planned to be introduced as shown in Scheme 42.  This was outlined earlier in Scheme 29 
with the primary alcohol of lactone 118 (Scheme 42) being converted to a carbon-carbon triple 
bond (127, Scheme 42).  This is proposed to occur by first oxidising the primary alcohol to an 
aldehyde, then the Wittig olefination which converts the aldehyde to a carbon-carbon double 
bond. Finally this will be oxidised to the desired carbon-carbon triple bond, which after later 
coupling steps, will become the Z-carbon-carbon double bond in RvE1 using Lindlar’s catalyst. 
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Scheme 42. The proposed formation of the Z-carbon-carbon double bond in RvE1. 
 
Firstly, (R)-124 (Scheme 41) and (S)-123 (Scheme 41) needed to be converted into lactone 118 
(Scheme 42).  Scheme 43 shows the proposed method of converting (R)-124 into the desired 
lactone.  First the ester group has to be hydrolysed to the corresponding carboxylic acid, and 
then, in the presence of acid, this will ring close to give the lactone.  The ring closure is an SN2 
reaction and due to the backside attack nature of the mechanism, the configuration is inverted 
therefore allowing (R)-epoxide to produce the desired (S)-lactone.  Effective orbital overlap, 
summarised by Baldwin’s rules, dictates that the 6-membered lactone ring is formed, as 
opposed to the 7-membered lactone ring.[58]  
 
 
Scheme 43. Proposed method of formation of 118 from (R)-124 via saponification and subsequent ring closing. 
 
The saponification of 124 (Scheme 43) to give 125 (Scheme 43) was completed using LiOH in 
a THF/H2O 1:1 mixture at room temperature.  After work up, the solvent was removed, but 
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125 (Scheme 43) was not isolated, instead the crude product was stirred in CH2Cl2 at -5°C and 
the addition of camphorsulfonic acid (CSA) triggered the ring closure to give 118 (Scheme 43). 
The initial conditions (Table 4, entry 1) were taken from a reaction in the literature using the 
same substrate,[53] but this gave a very disappointing 15% yield compared to the 86% yield 
quoted in the literature.  The reaction was repeated with these conditions several times to 
exclude human error, but a higher yield could not be obtained; therefore optimisation was 
required. 
The TLC of the crude product showed two compounds were present, one that corresponded to 
the starting epoxide 124 (Scheme 43) and one that corresponded to the lactone 118 (Scheme 
43) confirmed by 1H NMR spectroscopy.  The lack of a third spot on the TLC corresponding 
to the carboxylic acid 124 (Scheme 43) indicates that the 125 (Scheme 43) generated is then 
converted quantitatively to 118 (Scheme 43).  This suggested that the area of the reaction that 
needed to be addressed in the optimisation reactions was the conversion of the ester into the 
carboxylic acid in the first step. 
The easiest parameter to modify was reaction time.  Initially, only the reaction time of step (i) 
was manipulated, then when this yielded no improvement in yield, step (ii) was increased also, 
which unfortunately resulted in no isolatable yield at all (Table 4, entries 2 and 3 respectively). 
Returning to the original reaction times of 3 h and 2 h for the two steps respectively, but 
increasing the reaction temperature of the hydrolysis step to reflux showed an increase in yield 
to 25% (Table 4, entry 4).  
Further increase in yield occurred when the hydrolysis solvent system of THF/H2O was 
changed to the more polar, protic system of MeOH/H2O, still in a 1:1 ratio (Table 4, entries 5 
and 6).  When the reaction temperature was kept at room temperature the yield obtained was 
36%, but this was improved to 49% when the reaction was heated to reflux.  The remaining 
reaction mixture yielded unreacted starting material, 124. 
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Table 4. Optimisation conditions for the preparation of lactone 118 (Scheme 44). 
Entry Step (i)  
Time (h) 
Step (i)  
Temp (°C) 
Step (i) 
Solvent system  
Step (ii)  
Time (h) 
Overall 
yield (%) 
1 3 r.t. THF:H2O, 1:1 2 15 
2 24 r.t. THF:H2O, 1:1 2 15 
3 24 r.t. THF:H2O, 1:1 24 - 
4 3 70 THF:H2O, 1:1 2 25 
5 3 r.t. MeOH:H2O, 1:1 2 36 
6 3 70 MeOH:H2O, 1:1 2 49 
 
 
Scheme 44. Preparation of lactone 118 from R-124 with conditions described in entry 5 of Table 4. 
 
Whilst the optimisation reactions continued, the small quantity of lactone 118 (Scheme 44) that 
had been isolated was used to trial Swern oxidation conditions in order to oxidise the primary 
alcohol to its corresponding aldehyde. 
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Scheme 45. The attempted Swern oxidation of alcohol 118 to aldehyde 144. 
 
The conditions outlined in Scheme 45 were used for the attempted oxidation of the primary 
alcohol.  However, in this case the reaction was not successful, evidenced by the absence of a 
peak in the aldehyde region of the 1H NMR spectrum of the crude reaction mixture, and only 
starting material being recovered upon purification. 
As the synthesis of the RvE1 lactone fragment progressed, work was also undertaken alongside 
this on the synthesis of the RvE1 epoxide fragment, as will be discussed in the following 
section. 
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4.1.2 Synthesis of the RvE1 Epoxide Fragment 
As outlined earlier in Scheme 27 (shown in part below as Scheme 46), two different portions 
of the RvE1 chain are created from the epoxide fragment (109, Scheme 46).  This is able to 
happen as both portions contain the central component of a diene unit that neighbours a 
stereogenic centre with R configuration.  Being able to harbour two segments from one 
fragment could be invaluable in terms of yield, as it limits the number of steps required to reach 
the final coupling steps.  The diene unit of section 112 (Scheme 46) actually becomes a part of 
the triene unit in RvE1 when coupled with the carbon-carbon triple bond of the lactone 
fragment, via Sonogashira coupling. 
 
 
Scheme 46. The use of the epoxide fragment (109) in the synthesis of RvE1 (27). 
 
The stereogenic centre is introduced this time through the use of a compound from the chiral 
pool, originating from 1,2:5,6-di-O-isopropylidene-D-mannitol (117, Scheme 47).  Not only is 
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this protected D-mannitol cheap and easy to handle.  This chiral pool method also has the 
benefits of not requiring a resolution step later on in the synthesis where yield could be lost. 
The synthesis of the epoxide fragment, originating from the protected D-mannitol, was 
proposed to take 5 steps (Scheme 47). 
 
 
Scheme 47. Proposed reagents and conditions: (a) NaIO4, NaHCO3, CH2Cl2; (b) CrCl2, CHI3, THF; (c) 
PdCl2(PPh3)2, CuI, piperidine, ethynyltrimethylsilane; (d) 2M HCl, EtOH; (e) TsCl, DMAP, pyridine. 
 
The first step in the synthesis of the epoxide fragment is the cleavage of the central carbon-
carbon bond of the protected D-mannitol to give 2,3-O-isopropylidene-D-glyceraldehyde, 145 
(Scheme 48). 
 
 
Scheme 48. Cleavage of protected D-mannitol to give aldehyde 145 using NaIO4. 
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This reaction proceeded smoothly resulting in a good yield of 87%.  The cleavage of the central 
carbon-carbon bond occurs as the metaperiodate ion oxidises the secondary alcohol groups to 
aldehydes, rather than ketones, thereby breaking the carbon-carbon bond in the process.  This 
resulted in the formation of two equivalents of aldehyde 145 (Scheme 48) for every one 
equivalent of 117 (Scheme 48).  Therefore the reaction has a very high throughput.  It was easy 
to monitor the success of the reaction via the 1H NMR spectrum, due to the appearance of a 
distinctive doublet at 9.65 ppm signalling the presence of the aldehyde group, and the 
disappearance of a doublet of doublets at 3.74 ppm representing the protons at the 1 and 2 
position of 117 (Scheme 48). 
To ensure that this reaction did not affect the stereochemistry of the stereogenic centre, the 
specific rotation of aldehyde 117 was measured.  This gave a result of [α]𝟐𝟑
ᴅ
 = +87.5° (c 1.0, 
CHCl3), which concurs with the literature value of [α]
𝟐𝟑
ᴅ
 = between +70° and +80° (c 1.0-1.5, 
CHCl3),
[59] confirming that the stereochemistry of the stereogenic centre remained intact. 
Now that the stereochemistry was assured, the diene unit needed to be introduced.  This was 
proposed to be via a Wittig reaction (Scheme 49).  The Wittig reaction is a very reliable 
coupling reaction in which carbon-carbon double bonds are made.  The driving force of the 
reaction is the production of triphenylphosphine oxide as the phosphorus-oxygen bond is very 
strong.  This was hoped to produce 115 (Scheme 49) which contains one E carbon-carbon 
double bond, and then the carbon-carbon triple bond that could be functionalised later on to 
produce either 112 or 113 (Scheme 46) as needed. 
 
 
Scheme 49. Proposed Wittig coupling of aldehyde 145 and phosphonium salt 147. 
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The phosphonium salt (147, Scheme 49) required to produce 115 (Scheme 49) was not 
commercially available, and the bromide required for its synthesis (148, Scheme 51) is 
reasonably expensive, therefore a trial coupling was undertaken to ensure that aldehyde 145 
(Scheme 49) was suitable to undergo Wittig coupling.  Scheme 50 shows this practice coupling, 
where commercially available (carbethoxymethylene)triphenylphosphorane (149, Scheme 50) 
was used instead of bromide 148 (Scheme 49).  The carbon-phosphorus double bond means 
that this Wittig reagent exists as a phosphorane opposed to the phosphonium salt, and therefore 
base is not required in order for it to become the reactive ylide. 
 
 
Scheme 50. Wittig coupling practice reaction using commercially available 149 rather than 147 (Scheme 49). 
 
This practice coupling was successful, with a pleasing yield of 69%.  Even more pleasing was 
the fact that 150 was produced almost entirely in the desired E isomer, evidenced by the high 
coupling constants of 15.6 Hz for the vinyl protons, with only trace amounts of the Z isomer 
present.  The stereogenic centre remained intact demonstrated by the optical activity giving a 
result of [α]𝟐𝟑
ᴅ
 = +40.5° (c 1.0, CHCl3), which concurs with the literature value of [α]
𝟐𝟑
ᴅ
 = +38° 
(c 1.0, CHCl3).
[60] 
This success prompted the synthesis of the desired phosphonium salt 147 (Scheme 51).  The 
relevant bromide 148 (Scheme 51) was stirred overnight with triphenylphosphine in the dark, 
using toluene as the solvent.  This produced a crude yield of 78%, but unfortunately the product 
was unstable to recrystallisation and therefore the crude salt had to be carried forward into the 
Wittig coupling.  Due to this, the phosphonium salt needed to be used in excess (1.5 
equivalents) for the Wittig reaction. 
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Scheme 51. Preparation of phosphonium salt 147 for the use in the Wittig coupling outlined in Scheme 49. 
 
The preparation of desired compound 115 from phosphonium salt 147 (Scheme 52) proceeded 
smoothly and resulted in a 66% isolated yield. 
 
 
Scheme 52. The preparation of 115 in 66% yield using Wittig coupling. 
 
When studying the 1H NMR spectrum of 115 (Scheme 52), it was noted that the Wittig coupling 
produced a mixture of the E and Z isomers of the carbon-carbon double bond.  Coupling 
constants for Z isomers tend to be lower (around 5-14 Hz) than those for E isomers (around 12-
18 Hz).  The relevant portion of the 1H NMR spectrum is shown in Figure 28, from which the 
J coupling values for A and A* (E-115, Figure 28) were calculated to be 16 Hz, and those for 
B and B* (Z-115, Figure 28) were calculated to be 11.2 Hz.  This means that the A/A* protons 
are the E isomer, and the B/B* protons are the Z isomer. 
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Figure 27. A portion of the 1H NMR spectrum of 115 produced by Wittig coupling (Scheme 52), showing the 
protons of the carbon-carbon double bond. 
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Figure 28. The positions of protons A/A* and B/B* on E-115 and Z-115. 
 
The peak integration shown on Figure 27 shows that the ratio of E:Z isomers is approximately 
40:60 respectively.  The Wittig olefination was therefore deemed unsuitable for this synthesis, 
as the E isomer is required in the final RvE1 molecule, and not only is the Z isomer formed in 
this Wittig olefination, but it is also formed in the majority. 
The Takai olefination was investigated as a potential replacement, as it is quoted as being 
selective towards the E isomer.[61]  In order to test this, benzaldehyde was used as a trial 
substrate as shown in Scheme 53. 
 
 
Scheme 53. Takai olefination of benzaldehyde. 
 
The reaction was completed in anhydrous conditions.  Six equivalents of anhydrous 
chromium(II) chloride, two equivalents of iodoform, and one equivalent of aldehyde were 
required as stated in Takai’s original paper.   
The portion of the 1H NMR spectrum relevant to the protons of the carbon-carbon double bond 
of 152 (Scheme 53) is shown in 30.  The J coupling values for the C and C* (Z-152, Figure 29) 
protons were calculated to be 8 Hz, and those for D and D* (E-152, Figure 29) protons were 
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calculated to be 14 Hz.  This means that the C/C* protons are the Z isomer, and that the D/D* 
protons are the E isomer. 
Having determined which peaks correspond to which isomers, the peak integration shown on 
30 shows that the ratio of E:Z isomers is approximately 92:8 respectively, which concurred 
with that quoted in Takai’s original paper.[61]  This is a much more suitable ratio and therefore 
it was decided to use this method in the RvE1 synthesis as shown in Scheme 54. 
 
 
Figure 29. The positions of protons D/D* and C/C* on E-152 and Z-152. 
 
 
Scheme 54. Takai olefination of 145 to give E-116. 
 
The 96% yield quoted in Scheme 54 was achieved after optimisation experiments were carried 
out.  The original conditions (Table 5, entry 1) were those quoted in Takai’s original paper, and 
those that achieved the 99% yield shown in for the trial reaction of benzaldehyde (Scheme 53).  
However, when applied to aldehyde 145 this resulted in a disappointing 33% yield.  Increases 
in yield occurred when the reaction time was increased to 8 hours, and then 24 hours (Table 5, 
entries 2 and 3).  This gave a good yield of 87% when the reaction temperature was kept at 0°C 
from start to finish, but when the reaction temperature was allowed to gradually warm to room 
temperature over the 24 hour period (Table 5, entry 4), an excellent yield of 96% was obtained. 
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Figure 30. A portion of the 1H NMR spectrum of 152 produced by the Takai olefination (Scheme 53), showing 
the protons of the carbon-carbon double bond. 
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Table 5. Optimisation conditions for the Takai olefination shown in Scheme 54. 
Entry Time (hr) Start temp (°C) Finish temp (°C) Yield (%) 
1 3 0 0 33% 
2 8 0 0 52% 
3 24 0 0 87% 
4 24 0 r.t 96% 
 
1H NMR spectroscopy can be used to determine the completion of the Takai olefination; the 
doublet at 9.65 ppm representing the proton of the aldehyde group is removed, and a multiplet 
at 6.59-6.39 ppm, replaced it, representing the protons of the carbon-carbon double bond. 
The conversion of vinyl halide 116 to alkyne 115 was achieved via a Sonogashira coupling.  
Due to the mild nature of the reaction conditions (room temperature and short reaction time) 
this is a very useful method to use in this case due to the relative instability of vinyl halide 116.  
Sonogashira couplings require a catalytic Pd(0) complex, a Cu source (usually CuI) as a co-
catalyst, and also a base which usually doubles up as the reaction solvent.  A useful feature of 
the Sonogashira coupling is that although Pd(0) is required, a more stable and soluble Pd(II) 
derivative, such as such as Pd(PPh3)3Cl2, can be used instead.  This will then be reduced in situ 
to produce the catalytically active Pd(0) derivative.  This then follows the cycle outlined in 
Scheme 55 to couple together alkyne and halide species. 
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Scheme 55. Catalytic cycle of Sonogashira coupling, using Pd(PPh3)2Cl2 as the palladium source, CuI as the co-
catalyst and piperidine as the base. 
 
The Sonogashira coupling of 116 and 153 (Scheme 56) used Pd(PPh3)3Cl2 as the Pd(II) source 
that will be reduced in situ to Pd(0), CuI as the co-catalyst, and piperidine as the base.  The CuI 
was recrystallised from an aqueous saturated solution of NaI so as to ensure its purity before 
use.   
 
 
Scheme 56. Sonogashira coupling of vinyl halide 116 with ethynyltrimethylsilane (153) to produce alkyne 115. 
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The 1H NMR spectrum of vinyl halide 116 (Scheme 56) shows the protons of the carbon-
carbon double bond having a higher chemical shift than that normally expected due to the 
proximity of the iodide within the molecule.  As this iodide has been replaced with the much 
less electronegative ethynyltrimethylsilane group, these peaks reduce in chemical shift from 
the multiplet at 6.59-6.39 ppm shown in the starting material, to a doublet of doublets at 5.95 
ppm and a doublet at 5.61 ppm in the 1H NMR spectrum of the new product 115 (Scheme 56).  
The J coupling values of these protons were calculated to be 16 Hz, indicating that the E 
stereochemistry of the carbon-carbon double bond has remained intact. 
In order to convert 115 (Scheme 56) into the desired epoxide fragment 109 (Scheme 46), the 
protected diol unit must be manipulated into an epoxide.  The first step in doing so required the 
removal of the acetonide group serving as a protecting group for the diol, which was completed 
successfully in a near quantitative 98% yield (Scheme 57). 
 
 
Scheme 57. Deprotection of 115 to give diol 146. 
 
The conversion of diol 146 to epoxide 109 was planned to proceed via an Appel reaction 
forming a primary halide, which would then allow for the subsequent ring closure to the 
epoxide (Scheme 58).  The Appel reaction is a useful tool to convert alcohols to halides using 
a tetrahalomethane and triphenylphosphine, and primary alcohols are more reactive in this case, 
allowing for the desired selectivity shown in Scheme 58.  Halides are known to be excellent 
leaving groups, so it was proposed that the addition of base would deprotonate the secondary 
alcohol, and allowing the ring closure to the epoxide. 
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Scheme 58. Conversion of diol 146 to epoxide 155 via the Appel reaction and subsequent ring closure. 
 
The conversion was carried out as a one-pot procedure, with 154 not being isolated and instead 
used immediately in the formation of 155 (Scheme 58).  TLC confirmed that the Appel reaction 
proceeded near quantitatively, and when K2CO3 in methanol was added to initiate the ring 
closure, TLC indicated that a new product was present in the reaction mixture, although much 
of the bromide still remained. 
After work up, 1H NMR spectroscopic analysis indicated that in the epoxide ring had 
successfully been formed by peaks corresponding to protons in positions 1 and 2 of 155 
(Scheme 58) moving downfield in the spectrum.  Unsurprisingly, the TMS protecting group 
was notably absent on the 1H NMR spectrum, as the K2CO3 had removed this as well.  
However, the TMS group would soon be removed on the synthetic plan in order to manipulate 
the C-C triple bond into respective E and Z C-C double bonds, so this was not a problem.  The 
product was isolated in 11% yield. 
It was hypothesised that the low yield was due to the K2CO3 serving a dual purpose in removing 
the TMS group as well as forming the epoxide ring.  Therefore in an attempt to increase the 
yield of 155, the equivalents of K2CO3 were increased from 1 eq to 3 eq.  Unfortunately, the 
increase in equivalents of K2CO3 did not result in an increase in yield, with the aforementioned 
11% being the highest achieved.  It was decided that another base would be used to form the 
epoxide ring in the second step of Scheme 58, which would leave the TMS group intact.  Amine 
bases do not remove silicon protecting groups so it was hoped that an amine base would 
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overcome the problem but still form the epoxide ring.  Triethylamine, DBU and DBN were all 
trialled with no success. 
As demonstrated, there were continuing problems in the attempted synthesis of epoxide 155, 
and as a result other precursors to compound 114 (Scheme 27) were considered.  Cyclic sulfates 
are useful substrates for selective nucleophilic substitutions and therefore this functional group 
was considered as an alternative to the epoxide ring, as compound 114 (Scheme 27) could still 
be synthesised using the same chemistry.  The cyclic sulfate in this case was proposed to be 
synthesised from diol 146 (Scheme 58).  The reaction was initially carried out on a trial 
substrate that was cheaper to produce as shown in Scheme 59. 
 
 
Scheme 59. Synthesis of trial substrate 157 for use in the synthesis of cyclic sulfates. 
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Scheme 60. Synthesis of cyclic sulfate 158 from diol 157. 
 
TLC analysis showed that many compounds were present in the reaction mixture, making 
isolation of 158 difficult, with a disappointing isolated yield of only 4% (Scheme 60).  Due to 
this disappointing result coinciding in time with the shortcomings of the synthesis of the lactone 
fragment outlined in chapter 4.1.1, a new synthetic route towards RvE1 was devised and will 
be discussed in detail in chapter 4.2. 
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4.2 Second Synthetic Route Towards RvE1 
Due to both branches of the original synthetic plan towards RvE1 proving problematic as 
outlined in chapters 4.1.1 and 4.1.2, a new synthetic route towards RvE1 was devised (Scheme 
61). 
 
 
Scheme 61. New retrosynthetic plan towards RvE1. 
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The benefit of having as few steps as possible in a retrosynthetic plan has been outlined 
previously.  The original plan (Scheme 27) was proposed to be at least 19 steps long, without 
taking into consideration protection and deprotection steps that would be necessary for some 
of the final coupling reactions, whereas the new route (Scheme 61) was proposed to be only 12 
steps long which is a considerable reduction.  This should ensure that the overall yield of the 
synthesis is higher, presuming that the individual reaction yields are comparable.  Even if they 
are lower, it gives more scope for the individual reactions to produce lower yields and still 
enable the same amount of final product to be obtained.   
The final coupling reaction is planned to be a Sonogashira coupling between the alkyne formed 
in the right hand strand and the halide formed in the left hand strand (Scheme 61).  For ease of 
future discussion these fragments shall be referred to as the halide fragment (159, Figure 31) 
and the alkyne fragment (166, Figure 31). 
 
 
Figure 31. The key halide and alkyne fragments of the synthetic plan towards RvE1 outlined in Scheme 61. 
 
Both strands of this plan introduce compounds with stereogenic centres.  The centre with S 
configuration in the alkyne fragment (166) was proposed to be a stereospecific reduction of the 
ketone group, perhaps using a Noyori catalyst as this has precedent for similar compounds in 
the literature.[51]  The centre with R configuration at position 3 in the halide fragment was also 
proposed to be formed by a stereospecific reduction of a ketone group.  Whether or not this 
reduction will occur before or after the cross metathesis step is up for investigation.  The centre 
with R configuration at position 1 in the halide fragment (159) is proposed to be synthesised 
with the use of chiral additives in the indium coupling reaction. 
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It should be noted that the stereochemistry of the C-C double bond at the 2 position in the 
halide fragment is undetermined.  The corresponding C-C double bond in RvE1 requires Z 
stereochemistry.  However, the chemistry planned to achieve this (discussed in more detail in 
chapter 4.2.2) requires the coupling of aldehyde 163 and bromide 164, then subsequent 
rearrangement of the product to give the conjugated diene 161 (Scheme 61); due to the fact that 
the rearrangement of this particular product is novel, the stereochemistry of the C-C double 
bond cannot be assigned at this time.  If this reaction does in fact produce the C-C double bond 
with E stereochemistry, then due to the fragment nature of this project, then the product will 
still be useful in determining the bioactivity of modified RvE1 analogues and novel fragments.  
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4.2.1 Synthesis of the RvE1 Alkyne Fragment 
The initial synthetic plan to the alkyne fragment was proposed to take two steps (Scheme 62).  
This is a relatively short synthetic route towards this fragment due to the commercial 
availability of glutaric acid monomethyl ester chloride (168) which allows the starting material 
to closely resemble the desired product.  However, the route does see the introduction of a 
stereogenic centre (S configuration) and therefore still carries synthetic challenges.  An 
asymmetric reduction using a Noyori catalyst was initially chosen to introduce this 
stereocentre. 
 
 
Scheme 62. Proposed reagents and conditions: (a) bis(trimethylsilyl)acetylene, AlCl3, CH2Cl2; (b) RuCl(p-
cymene)[(S,S)-Ts-DPEN], i-PrOH. 
 
The first reaction in the synthesis was proposed to be a Lewis acid mediated reaction between 
glutaric acid monomethyl ester chloride and bis(trimethylsilyl)acetylene.  AlCl3 was chosen as 
the Lewis acid.[62]  This reaction was trialled on a 1 mmol scale (Scheme 63).  A mixture of 168 
and 169 in CH2Cl2 was added dropwise to a suspension of AlCl3 in CH2Cl2 at 0°C.  When full 
addition had occurred, the reaction mixture was allowed to stir at 0°C for a further 0.5 h before 
being quenched with ice and saturated aqueous citric acid.  This worked well in 70% yield and 
was simple to isolate by extraction into diethyl ether followed by column chromatography.   
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Scheme 63. Conditions for the synthesis of alkyne 167 from commercially available glutaric acid monomethyl 
ester chloride on 1 mmol scale.[62] 
 
However, difficulties arose during scale up from 1 mmol to 12 mmol.  Using the conditions 
outlined in Scheme 63, the yield decreased considerably to only 21% which was far too low to 
continue forward in the synthesis, with the rest of the reaction material being returned as 
uncharacterised by-products.  This was overcome by lowering the reaction temperature from 
0°C to -15°C, and lengthening the reaction time from 0.5 h to 1 h.  These changes bought the 
yield back in line with the trial experiments at 72% (Scheme 64). 
 
 
Scheme 64. Adapted conditions from Scheme 63 suitable for the scaled up synthesis of alkyne 167. 
 
With 167 synthesised, it was now time to introduce the stereogenic centre by asymmetrically 
reducing the ketone.  Before this however, the racemic reduction was sought to ensure that the 
ketone could be selectively reduced over the methyl ester. Also the racemic compound would 
be required later in the determination of the ee of S-166 by HPLC. 
NaBH4 was chosen as the reducing agent to obtain the racemic alcohol as it is readily available 
and reported to be selective to ketones over ester groups.  It is also easy to handle as it is not 
sensitive to air or water, and reactions can take place at room temperature. 
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Alkyne 167 was suspended in ethanol and stirred at room temperature.  To this, a suspension 
of NaBH4 in distilled water was added dropwise, and then the reaction mixture was allowed to 
stir for 1 h (Scheme 65).  The reaction was finally quenched with a mix of ice water and HCl 
before the product was isolated.  Unfortunately, the desired racemic alcohol was not found to 
be produced under these conditions.  Instead, diol 170 (Scheme 65) was obtained in 66% yield. 
 
 
Scheme 65. Reduction of 167 with NaBH4 (1.1 eq). 
 
The production of diol 170 in a relatively short time period, is therefore unexpected.  Even so, 
the ketone should still be the preferred group to reduce, therefore the equivalents of NaBH4 
were reduced from 1.1 eq to 0.75 eq in an attempt to selectively reduce the ketone group 
(Scheme 66).  This did allow for the desired racemic-166 to be synthesised, but in a 
disappointing 19% yield, with diol 170 still being the predominant product formed under these 
conditions. 
 
 
Scheme 66. Reduction of 167 with NaBH4 (0.75 eq). 
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Another reducing agent capable of reducing carbonyl groups is DIBAL-H.  DIBAL-H is a 
much stronger reducing agent that NaBH4, well known for being able to reduce ester groups 
which is obviously undesirable in the synthesis of racemic-166.  However, DIBAL-H has only 
one hydride ion to donate and it was hypothesised that the ketone would be the more reactive 
site of reduction if DIBAL-H was trialled on alkyne 167.  A short reaction time of 0.5 h was 
also proposed (Scheme 67) in order to limit the likelihood of ester reduction.  After the reaction 
was complete, the reaction mixture was quenched with methanol and distilled water before 
being extracted with diethyl ether. 
 
 
Scheme 67. Conditions for the reduction of 167 with DIBAL-H. 
 
These conditions did produce racemic-166 in 30% yield.  However, they also yielded lactone 
171 (Scheme 67) as the major product in 43% yield.  This resulted in a total yield of the 
reduction of 73%, with the other material being recovered as starting material. 
The production of lactone 171 is interesting, as this shows that more than the 30% isolated 
racemic-166 was formed by the reaction, but has undergone an intramolecular esterification to 
form the lactone.  The fact that the lactone was isolated in a higher yield than its straight chain 
form, suggests that S-166 may also exist in this form, and therefore racemic-171 may also be 
useful in the determination of the ee of S-171, depending on which form it takes. 
If the lactone is the preferred form after the reduction of the ketone group, then this is not a 
problem going forward in the synthesis; 171 is the same structure as the lactone fragment from 
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the first retrosynthetic plan towards RvEl discussed in chapter 4.1, and therefore the original 
chemistry required to couple the lactone to the other fragment (Sonogashira coupling with 
subsequent ring opening), can be applied here also. 
With the racemic compounds in hand, focus turned to the asymmetric reduction of the ketone.  
Noyori catalysts, such as the one shown in Figure 32, have a ruthenium centre that coordinates 
to the oxygen of the ketone group.  The chirality of the ligands causes steric hindrance on one 
face of the ketone, therefore only allowing hydrogenation to occur on the other, thereby causing 
enantioselective reduction of the ketone.  
 
 
Figure 32. The structure of the Noyori catalyst RuCl[(S,S)-TsDPEN](p-cymene). 
 
Applying that to 167, a literature precedent was followed that claimed to obtain S-166 in 82% 
yield with 98% ee.[62]  The Noyori catalyst used is RuCl[(S,S)-TsDPEN](p-cymene) (172, 
Figure 32) with the conditions outlined in Scheme 68; it was necessary to distil the isopropanol 
before use to ensure dry reaction conditions. 
 
 
Scheme 68. Attempted synthesis of S-166 using a Noyori catalyst and i-PrOH according to literature 
precedent.[62] 
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Unfortunately these conditions yielded no reaction.  TLC analysis, confirmed by 1H NMR 
spectroscopy of the crude product, showed that only the starting material was present in the 
reaction mixture after the 2 h time period stated in the literature.  The reaction was left to stir 
overnight, but still no reaction took place.  In their synthesis of RvE1, Allard et al. 
asymmetrically reduced the isopropyl ester form of 167 using the same catalyst and solvent 
system, but starting the reaction at 0°C and bringing it up to rt over a 2 h period.[46]  This 
modification was applied to methyl ester 167 but still no reaction took place.   
Another precedent was found in the literature, utilising the same catalyst with formic 
acid/triethylamine (1:1) as the solvent system.[63]  These conditions were applied to 167, but 
unfortunately, as with the conditions shown in Scheme 68, no reaction occurred. 
After experiencing no success using the Noyori catalyst, another method of asymmetric 
reduction was considered.  The Midland reduction utilises the chiral Alpine borane to 
enantioselectively reduce ketones.  In order to obtain an S-stereocentre, the S-Alpine borane is 
required (174, Figure 33). 
Conditions found in the literature for a similar substrate system were applied to 167 as shown 
in Scheme 69. [64] 
 
 
Figure 33. The structures of R-Alpine borane (173) and S-Alpine borane (174). 
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Scheme 69. Attempted synthesis of S-166 using S-Alpine-Borane. 
 
As with the attempted reductions using a Noyori catalyst (Scheme 68) TLC and 1H NMR 
spectroscopic analysis of the crude product indicated that no reaction had taken place and only 
starting material was returned.   
These results are unusual and suggests that there is an underlying reason common to all of the 
failed reductions, for example, perhaps the reaction set-up is not dry enough, and even trace 
amounts of oxygen or moisture are causing the reduction to fail.   
Despite these shortcomings, this thread is still promising as the potential problem with dryness 
should be simple enough to rectify if this is indeed the issue.  There are also several more 
conditions in the literature that could be trialled on this substrate.  For example, Rodriguez and 
Spur used the Noyori catalyst discussed earlier, along with CTABr as a phase-transfer catalyst 
and sodium formate as the reducing agent[48].  Work is ongoing in the group to continue this 
thread.  
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4.2.2 Synthesis of the RvE1 Halide Fragment 
The initial synthetic plan to the halide fragment was proposed to take 9 steps as shown in 
Scheme 70. 
 
 
Scheme 70. Proposed reagents and conditions: (a) vinylmagnesium bromide, THF; (b) 48% HBr; (c) 3-
(trimethylsilyl)-2-propynal, In, (+)-Cinchonine, THF/hexane; (d) In(OTf)3, CH2Cl2; (e) Hoveyda-Grubbs 2nd 
generation catalyst, 1-penten-3-one, CH2Cl2; (f) RuCl(p-cymene)[(R,R)-Ts-DPEN], i-PrOH; (g) TBAF, NH4Cl, 
THF; (h) trans-1,2-dichloroethylene, PdCl2(PPh3)2, CuI, piperidine; (i) Na, NH3(l). 
 
This route uses indium chemistry which is an attractive alternative to other organometallic 
reagents. This is because organoindium compounds are relatively stable compared to their main 
group metal counterparts, which can be difficult to handle due to their sensitivity to air and 
moisture.  Also in some instances, reactions using organoindium compounds can proceed in 
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water alone and are therefore environmentally friendly as no organic solvents are required.  
Other coupling steps include Sonogashira coupling, the benefits of which have been discussed 
previously, and also cross-metathesis using Hoveyda-Grubbs 2nd generation catalyst (180, 
Figure 34) and literature conditions developed for use with conjugated dienes.[65] 
 
 
Figure 34. Hoveyda-Grubbs 2nd generation catalyst. 
 
As discussed in the introduction to chapter 4.2, the two stereogenic centres with R configuration 
are introduced here.  The first during Scheme 70, step c, is through the use of a chiral ligand.  
Loh and co-workers reported that good yields and enantioselectivity were achieved through the 
use of either (-)-cinchonidine for R configuration, or (+)-cinchonine for S configuration.[66][67]  
However, this method has been reported to produce lower enantioselectivities when applied to 
α,β-unsaturated aldehydes and so may be unsuitable for this substrate.  If that is the case, there 
are other chiral ligand additives that have been reported, such (1S,2R)-(+)-2-amino-1,2-
diphenylethanol.[68][69][70] 
It can be seen that the conditions stated in Scheme 70, step c, generate the S-isomer opposed to 
the R-isomer; this is due to the fact that the subsequent reaction (Scheme 70, step d) of 
converting the non-conjugated diene to the conjugated species has been found to invert 
stereochemistry.[9]  Therefore, the desired R-isomer will be produced during this conversion. 
The second stereogenic centre is introduced during Scheme 70, step f, via asymmetric reduction 
by Noyori catalyst, drawing parallels with the introduction of the S-centre in the synthesis of 
the alkyne fragment (chapter 4.2.1).   
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Bromide 164, which is to be coupled with 3-(trimethylsilyl)-2-propynal (163, Scheme 74), is 
not commercially available, and so needed to be synthesised from alcohol 165 (Scheme 72).  
1,4-Pentadien-3-ol (165) is commercially available but being at the start of a total synthesis 
will be required in large quantities, so having proven that it can be used to successfully produce 
bromide 164, work was undertaken to synthesise 1,4-pentadien-3-ol in bulk, using cheaper 
commercially available starting materials.  A literature procedure was followed whereby 1M 
vinylmagnesium bromide in THF (2 eq) was stirred at 0°C under nitrogen, and ethyl formate 
added dropwise over 1 h whilst ensuring that the reaction temperature did not exceed 15°C.  
After addition was complete, the reaction temperature was bought up to room temperature and 
allowed to stir for a further 1 h.[71]  After workup, 1,4-pentadien-3-ol (165) was isolated in 71% 
yield by bulb-to-bulb distillation (Scheme 71). 
 
 
Scheme 71. Synthesis of alcohol 165 from 1M vinylmagnesium bromide (181) and ethyl formate (175). 
 
The reaction shown in Scheme 71 was also trialled with the Grignard reagent generated in situ, 
with the starting materials being 1M vinyl bromide in THF solution and magnesium turnings 
with catalytic iodine.[71]  This produced 1,4-pentadien-3-ol in a lower 59% yield, so the reaction 
was taken forward using the commercially available vinylmagnesium bromide solution as 
outlined in Scheme 71. 
With a method for the production of 1,4-pentadien-3-ol in hand, the bromide could now be 
synthesised.  1,4-Pentadien-3-ol (165) was cooled to -15°C and stirred whilst 48% HBr solution 
was added dropwise over 1 h.[71]  Once addition was complete, the solution was stirred at -15°C 
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for a further 1 h, producing bromide 164 in 66% yield after work up and isolation via bulb-to-
bulb distillation. 
 
 
Scheme 72. The synthesis of bromide 164 from alcohol 165 and aqueous HBr. 
 
The reaction required to synthesise branched diene 176 from bromide 164 and 3-
(trimethylsilyl)-2-propynal (Scheme 70) utilises organoindium chemistry.  Organometallic 
chemistry is a useful synthetic tool in organic chemistry, but can be made problematic by most 
organometallic reagents, such as MeLi or Grignard reagents, being sensitive to air and 
moisture, therefore making their handling difficult.  Also, these reagents can show poor 
compatibility with functional groups such as carbonyls and hydroxyl groups which can cause 
issues with their application to organic synthesis; in particular, consider RvE1 which contains 
three hydroxyl groups and a carboxylic acid functionality which would make working with 
reagents such as these problematic.  In contrast, organoindium reagents are mild and relatively 
stable, whilst also boasting excellent compatibility towards a number of functional groups, 
including the aforementioned problematic hydroxyl groups.[8]   
An insensitivity to air means that unlike other metals, such as magnesium and zinc, an oxide 
layer does not form on the surface of indium metal, meaning that indium can be used directly 
in reactions without the need for special pre-preparation.  Additionally, ambient temperature 
indium is unreactive to water, meaning that not only are tedious drying methods not required, 
but also organoindium reactions can be performed in entirely aqueous media which negates the 
need for environmentally unfriendly organic solvents.  Another benefit of organoindium 
chemistry is that indium metal and its derivatives are less toxic than other organometallic 
counterparts, or even nontoxic, which is extremely advantageous for total synthesis that is 
being subjected to biological testing.[8]   
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Scheme 73. Allylindium species formed in organic[72] and aqueous[73] media. 
 
The allylindium reagent generated is different depending on whether the reaction takes place 
in organic or aqueous media.  Scheme 73 shows the indium sesquihalide (183) generated in 
organic media such as DMF or THF,[72] and also allylindium(I) (184) generated in aqueous 
media.[73]  In the interests of being green, the organoindium coupling used in the synthesis of 
161 (Scheme 70) was initially trialled with water as the solvent. 
When (E)-5-bromopenta-1,3-diene (bromide 164, Scheme 72) is treated with indium metal and 
subsequently subjected to a carbonyl, it has been found to result in γ-pentadienylation, and 
therefore the non-conjugated species is formed.[74]  Due to this, an extra step is required in the 
synthesis of conjugated diene 161 (Scheme 70, step d) in order to achieve the desired 
conjugated diene system shown in RvE1.  The same group also discovered when working with 
(E)-5-bromopenta-1,3-diene (bromide 164, Scheme 72), that the addition was significantly 
slower than allylindium.  The addition at room temperature with allylindium usually requires 
12-24 h, whereas it was found that this had to be increased considerably to 72 h in the case of 
(E)-5-bromopenta-1,3-diene.[75] 
The coupling of 3-(trimethylsilyl)-2-propynal (163) and bromide 164 was initially trialled in a 
racemic manner in order to ensure that the conditions suggested in the literature are suitable 
with this combination of aldehyde and bromide (Scheme 74). 
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Scheme 74. Coupling of 3-(trimethylsilyl)-2-propynal (163) and bromide 164 using indium metal with distilled 
water as the solvent. 
 
The reaction proceeded smoothly, and after workup the non-conjugated diene 176 was isolated 
in 51% yield.  This yield was lower than wanted, so the solvent was changed to absolute 
ethanol.  Ethanol still has the polar and protic properties as water, but is an organic solvent so 
it was selected in order to determine if the yield could be improved in this manner. 
 
 
Scheme 75. Coupling of 3-(trimethylsilyl)-2-propynal (163) and bromide 164 using indium metal with absolute 
ethanol as the solvent. 
 
This change increased the yield to 67% which was deemed suitable to take racemic 176 forward 
to attempt the thermodynamic conversion to the conjugated diene (Scheme 76).   
Loh and co-workers explored the usefulness of indium reagents to promote this thermodynamic 
conversion as their group had history in indium chemistry research; given that the formation 
of 176 (Scheme 75) was achieved through organoindium chemistry, it was decided that this 
same logic could apply here.  Table 6 shows the reagents trialled, and the result that In(OTf)3 
proved to be highly efficient in catalysing this conversion.[9] 
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Table 6. Evaluation of various indium reagents for the thermodynamic conversion of branched-185 to linear-186 
by Loh and co-workers, 2001.[9] 
Entry Indium Reagent Yield (%) 
1 In, allyl bromide, HMPA[a] No reaction 
2 InF3
[b] No reaction 
3 InCl3
[b]
 No reaction 
4 In(OTf)3
[b]
 78 
[a] branched-183 (0.5 mmol), In (1.0 mmol), allyl bromide (1.5 mmol), HMPA (7.5 mmol), THF (5 mL). [b] 
branched-183 (0.5 mmol), Lewis acid (0.05 mmol), CH2Cl2 (4 mL). 
 
These conditions were applied to the conversion of branched 176 to linear 161 (Scheme 76).  
The reaction was trialled at both room temperature and reflux for 24 h but both conditions 
produced no reaction and only starting material was recovered. 
 
 
Scheme 76. The attempted thermodynamic conversion of non-conjugated diene 176 to conjugated diene 161 
using catalytic In(OTf)3. 
 
As alluded to previously, the branched chain γ-adducts are the kinetically favoured products of 
this addition, with the linear α-adducts the thermodynamically favoured products.  It could be 
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possible that the very strong π-system of the C-C triple bond in 176 offers a stabilising effect 
and therefore the branched chain species is already thermodynamically stable.  Therefore, a 
different substrate was proposed whilst still utilising the same indium chemistry. 
 
 
Scheme 77. Coupling of glycolaldehyde dimer (186) and bromide 164 using indium metal. 
 
Glycolaldehyde dimer was chosen as the new substrate.  This produced diol 188 (Scheme 77) 
in a good yield of 72%, and also with the added bonus of only 0.5 eq of glycolaldehyde dimer 
required to produce 1 eq of 188.  It was planned that the primary alcohol group could be 
manipulated later on in order to resemble the plan outlined at the beginning of the chapter. 
 
 
Scheme 78. Silyl protection of the primary alcohol group of diol 188. 
 
The primary alcohol group of diol 188 was protected with a bulky silyl group (Scheme 78) 
before the thermodynamic conversion to its conjugated diene form was attempted.  This was 
in order to ensure that no side reaction took place due to the second alcohol group present in 
the molecule. 
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Scheme 79. The attempted thermodynamic conversion of non-conjugated diene 189 to conjugated diene 190 
using catalytic In(OTf)3. 
 
As with the previous example, the conversion was attempted at both room temperature and 
reflux.  However, this new substrate still yielded no reaction (Scheme 79).   
 
 
Figure 35. The positions of the variations in R group in the work by Loh and co-workers on the In(OTf)3 
catalysed thermodynamic conversion of homoallylic alcohols.[9] 
 
The work of Loh et al. on the use of In(OTf)3 to promote this conversion was undertaken on 
many substrates with varying R1 and R2 groups (at the positions demonstrated in Figure 35) 
with varying success.  However, it was noted that no substrate produced by addition to 5-
bromopenta-1,3-diene, and therefore producing an R2 of -CH=CH2, was trialled.  This 
prompted a more in-depth look at the reaction mechanism of the thermodynamic conversion in 
order to determine if this difference in R2 group could be causing the reaction failure. 
When Loh et al. analysed the reaction outlined in Table 6, entry 4, the 1H NMR spectrum of 
the crude reaction mixture showed an aldehydic proton at a chemical shift of 9.61 ppm.  This 
lead them to believe that the reaction proceeded via a retro-process that generated the free 
aldehyde in situ.[9]  The group investigated these claims and proposed a mechanism for the 
rearrangement (Scheme 80).[76]  The proposed mechanism starts with the Lewis acid 
coordinating to the oxygen of the alcohol group, causing it to breakdown into the aldehyde.  
This aldehyde then reacts with the alcohol remaining in the reaction mixture to set in motion 
the rearrangement, before being reformed in the final step.   
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Scheme 80. Proposed mechanism for the rearrangement from kinetic branched product to thermodynamic linear 
product.[76] 
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Originally, the reaction mechanism was consulted to ascertain whether the R1 or R
2 group 
(Figure 35) could affect the success of the reaction, but upon studying the reaction scheme 
another idea was formed.  As the aldehyde serves a catalytic function after being generated by 
the Lewis acid, it was proposed that the failure of the rearrangements described in Scheme 76 
and Scheme 79 could be due to this aldehyde not being generated, and therefore if a catalytic 
amount of the appropriate aldehyde was added to the reaction mixture, then this could result in 
these rearrangements working. 
 
 
Scheme 81. The thermodynamic conversion of branched-176 to linear-161 using catalytic In(OTf)3 and catalytic 
3-(trimethylsilyl)-2-propynal (163). 
 
The rearrangement with the original substrate (176, Scheme 76) was reattempted, but with the 
addition of 0.1 eq of 3-(trimethylsilyl)-2-propynal (163) (the aldehyde used to synthesise 176, 
Scheme 74).  The reaction mixture was stirred at room temperature overnight, and after workup 
conjugated diene 161 was isolated in 53% yield.  The reaction was also repeated under reflux 
but in this instance the yield actually dropped to 49%.   
This very pleasing result led to the question of whether the addition of catalytic aldehyde could 
improve the efficiency of the rearrangement for other substrates too.  Chapter 4.3 discusses 
these investigations in detail and highlights the difference in reaction efficiency with or without 
the presence of catalytic aldehyde. 
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4.3 Methodology Development 
As discussed previously there are several wide-ranging benefits of using indium in the field of 
organometallic chemistry.  Not only is indium not sensitive to air and moisture as many other 
organometallic reagents are, but it and its compounds are virtually all non-toxic.  They also 
have excellent compatibility with a wide range of functional groups, which makes indium a 
very useful tool in synthetic chemistry. 
In chapter 4.2.2, the reaction mechanism (Scheme 80, page 100) of the Lewis acid catalysed 
thermodynamic conversion of branched chain homoallylic alcohols to their linear counterparts 
was studied, and it was discovered that the homoallylic alcohol was broken down into its 
respective aldehyde, which then acted in a catalytic manner promoting the conversion of other 
alcohol molecules in the reaction mixture to the linear product.  This provided the notion that 
a catalytic amount of the aldehyde could be added to the reaction mixture in order to improve 
the efficiency of the conversion.  Initial investigations (Scheme 81, chapter 4.2.2) showed that 
the addition of 0.1 eq of the relevant aldehyde resulted in a reaction that had not previously 
yielded any product (Scheme 76) now producing a 53% yield.  This is obviously a significant 
improvement and prompted the question of whether the addition of a catalytic amount of the 
relevant aldehyde to the reaction mixture could improve the efficiency of the conversion of 
other substrates too. 
To investigate this, first a range of branched chain alcohols must be synthesised.  A range of 
substrates were chosen as outlined in Table 7.  The reaction conditions used were those used 
to synthesise 176 (Scheme 75), with absolute ethanol as the solvent stirred at room temperature 
for 72 h. 
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Table 7. Yields obtained from of the pentadienylation of several aldehydes using indium metal in EtOH. 
Entry Aldehyde Product Yield (%) 
1 
 
(163) 
 
(176) 
67 
2 
 
(207) 
 
(208) 
76 
3 
 
(209) 
 
(210) 
90 
4 
 
 
(211) 
 
(212) 
69 
5 
 
(213) 
 
(214) 
90 
6 
 
(215) 
 
(216) 
71 
7 
 
(217) 
 
(218) 
89 
104 
 
8 
 
(219) 
 
(220) 
5 
9 
 
(221) 
 
(222) 
- 
10 
 
 
(223) 
 
(224) 
49 
11 
 
 
 
 
(225) 
 
 
(226) 
68 
 
The synthesis of these branched chain substrates occurred in generally good yields with two 
exceptions; entries 8 and 9 (Table 7) where the initial aldehydes were 4-methoxybenzaldehyde 
and 4-nitrobenzaldehyde respectively.  The electron donating properties of the methoxy group 
on 4-methoxybenzaldehyde (219, Table 7) form deactivating resonance structures that decrease 
the delta positive characteristic of the carbonyl carbon, therefore making it less susceptible to 
nucleophilic attack.  For this reason, the low yield for the reaction shown in entry 8, Table 7 
was to be expected.  The nitro group on 4-nitrobenzaldehyde is strongly electron withdrawing; 
if this was the reason for the reaction failure then it would also be expected that entries 6, 7 and 
8, Table 7 (4-bromobenzaldehyde, 3-bromobenzaldehyde and 2-bromobenzaldehyde 
respectively) would also fail as their bromo group is also electron withdrawing.  However, as 
these entries produced excellent yields (90%, 71% and 89% respectively), which suggests that 
there is another reason for the reaction failure.  It is likely that this reason is the indium 
preferentially reducing the nitro group rather than facilitating the pentadienylation.[77]  
With the branched diene starting materials in hand, it was necessary to determine the optimum 
conditions for the thermodynamic conversion to their conjugated diene counterparts.  A series 
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of optimisation reactions were carried out as detailed in Table 8, using branched diene 210 
(entry 3, Table 7) due to it being produced in a high yield and also the low cost of the starting 
material benzaldehyde. 
The optimisation reactions trialled different Lewis acids, temperatures, reaction times, and 
equivalents of aldehyde added to the reaction, the details of which are outlined in Table 8. 
 
 
Table 8. Optimisation experiments for the thermodynamic conversion of non-conjugated diene 210 to its 
conjugated species 227, trialling different Lewis acids, reaction times and temperatures, and the presence of 
catalytic aldehyde.  Aldehyde used was benzaldehyde.  Lewis acids were used in 10 mol % concentration. 
Entry Lewis Acid  
(10 mol %) 
Aldehyde 
concentration 
 (eq.) 
Reaction 
Time 
(h) 
Reaction 
Temp 
(°C) 
Yield 
(%) 
1 - - 24 rt - 
2 - - 24 40 - 
3 - 0.1 24 rt - 
4 - 1 24 rt - 
5 - 1 24 40 - 
6 In(OTf)3 - 24 rt 23 
7 AlCl3 - 24 rt 22 
8 Sn(OTf)2 - 24 rt 23 
9 In(OTf)3 - 5 rt 11 
10 In(OTf)3 - 5 40 9 
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11 In(OTf)3 - 24 40 19 
12 In(OTf)3 0.1 24 rt 67 
13 In(OTf)3 0.2 24 rt 65 
14 In(OTf)3 0.5 24 rt 67 
15 In(OTf)3 1 24 rt 67 
16 In(OTf)3 0.1 24 40 63 
17 In(OTf)3 0.1 48 rt 66 
 
Firstly, the reaction was trialled without the presence of either Lewis acid or aldehyde at both 
room temperature and reflux; unsurprisingly, only starting material was returned and no 
reaction took place (entries 1-2, Table 8). 
The next variable to be investigated was whether the presence of the Lewis acid was necessary, 
after the initial reaction only began to work after the addition of (trimethylsilyl)-2-propynal 
(Scheme 81, chapter 4.2.2).  Catalytic and stoichiometric amounts of benzaldehyde were added 
to the reaction without the presence of a Lewis acid, at room temperature and reflux, but only 
starting material was returned (entries 3-5, Table 8). 
These results showed that the presence of a Lewis acid in the reaction was required, the 
investigations moved on to whether the identity of this Lewis acid affected the reaction.  As 
mentioned previously, In(OTf)3 was selected to offer an aspect of continuity after the initial 
indium pentadienylation step, and AlCl3 and Sn(OTf)2 were selected due to their availability 
in the laboratory.  After a 24 h reaction at room temperature with no aldehyde present, the 
yields produced by each Lewis acid were very similar.  In(OTf)3 was taken forward to test the 
other variables in order to retain the afore mentioned continuity as AlCl3 and Sn(OTf)2 did not 
offer any improvement (entries 6-8, Table 8). 
Following the selection of the Lewis acid, time and temperature were examined.  The two time 
periods were 5 h and 24 h, and the two temperatures were room temperature and reflux (40°C).  
The room temperature reactions produced a higher yield than reflux for both reaction times, 
with the original 24 h room temperature reaction providing the highest yield of 23% (entries 6, 
9-11, Table 8). 
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The combination of Lewis acid and aldehyde was then optimised by trialling whether the 
aldehyde best worked in catalytic or stoichiometric amounts.  The reactions trialled 0.1, 0.2, 
0.5 and 1 equivalent of benzaldehyde alongside 10 mol % In(OTf)3 in a 24 h room temperature 
reaction.  The results for each reaction were very similar, with all but one giving the same yield 
of 67%.  This shows that only a catalytic amount of aldehyde is required, and therefore 0.1 
equivalent of aldehyde was selected as the optimum as greater volumes offered no 
improvement (entries 12-15, Table 8). 
These conditions were subjected to two final attempts to improve the yield, first by attempting 
the reaction at reflux as initial reactions under reflux did not contain the combination of both 
Lewis acid and aldehyde, and secondly by increasing the room temperature reaction time to 48 
h.  Neither of these offered any improvement (entries 16-17, Table 8). 
The results of these optimisation experiments show that the optimum reaction conditions for 
thermodynamic conversion are 10 mol % In(OTf)3, 10 mol % aldehyde, 24 h, room temperature 
(entry 12, Table 8).   
It should be noted that the rest of the reaction material in each optimisation experiment returned 
unreacted starting material, which could be recovered and reused in a subsequent 
rearrangement reaction, thereby increasing the throughput of the reaction. 
These conditions will now be applied to the branched chain dienes made previously (Table 7).  
For each example, the reaction was completed both with and without the presence of catalytic 
aldehyde to highlight any improvement that can be attributed to it (Table 9). 
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Table 9. Comparison of yield for the thermodynamic conversion of non-conjugated dienes to their respective 
conjugated species, with and without catalytic aldehyde.  Aldehyde used in each example was the aldehyde used 
to synthesise non-conjugated starting material as shown in Table 7.  
Entry Branched starting 
material 
Linear product Yield (%) 
– no 
aldehyde 
Yield (%) 
– 0.1 eq 
aldehyde 
1 
 
(176) 
 
(161) 
- 53 
2 
 
(208) 
 
(229) 
32 60 
3 
 
(210) 
 
(227) 
38 67 
4 
 
(212) 
 
 
(230) 
- - 
5 
 
(214) 
 
(231) 
49 71 
6 
 
(216) 
 
(232) 
- 69 
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7 
 
(218) 
 
(233) 
56 72 
8 
 
(220) 
 
(234) 
- - 
9 
 
(224) 
 
(235) 
- - 
10 
 
(226) 
 
 
 
(236) 
- - 
 
The first thing to note about the results shown in Table 9 is that the 1H NMR spectra confirm 
that the conjugated dienes produced have E stereochemistry, as the spectra show J coupling 
values of >15 Hz in each case for the necessary alkenyl protons. 
Entries 1, 2, 3, 5, 6, and 7 (Table 9) showed successful conversions from the non-conjugated 
dienes to their respective conjugated species.  In the cases of entries 2, 3, 5 and 7 (Table 9), the 
conversion did work without the catalytic aldehyde present, however when the reactions were 
repeated with the presence of catalytic aldehyde the yields were substantially increased (32% 
to 60%; 38% to 67%; 49% to 71%; 56% to 72%, respectively).  The two most interesting results 
were entries 1 and 6 (Table 9) where the reaction without catalytic aldehyde yielded no 
conjugated diene, only returning starting materials; when the catalytic aldehyde was added, 
these reactions yielded the conjugated diene in pleasing 53% and 69% yields respectively. 
Entries 4, 8, 9 and 10 (Table 9) failed to convert the non-conjugated dienes to their respective 
conjugated species in reactions both with and without the catalytic aldehyde.  In the case of 
entry 8, this result is perhaps unsurprising due to the poor yield obtained when synthesising 
branched chain 220 (Table 7).  As stated previously, the electron donating properties of the 
methoxy group on 4-methoxybenzaldehyde (219, Table 7) form resonance structures that 
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decrease the delta positive characteristic of the carbonyl carbon, therefore making it less 
susceptible to nucleophilic attack.  This same reasoning can be applied to entry 9 (Table 9), as 
the oxygen in the furan group has the same electron donating properties as the methoxy group; 
indeed the yield for the synthesis of branched 224 was also low. 
Entries 4 and 10 (Table 9) were a little more difficult to explain; the synthesis of their branched-
chain counterparts produced good yields of 69% and 68% respectively.  One hypothesis 
concerns the hybridisation of the alpha-carbon of the aldehyde.  In the cases of the successful 
entries the alpha-carbon is either sp or sp2 hybridised, the one exception being entry 2 (Table 
9) where the alpha-carbon is sp3 hybridised, but is a tertiary centre.  In the cases of entries 4 
and 10 (Table 9), the alpha-carbon is sp3 hybridised, and secondary centres.  It is proposed that 
hyperconjugation of electrons in C-H bonds, where non-tertiary sp3 alpha carbons are present, 
leads to an increase in electron density about the carbonyl carbon (in much the same way that 
a tertiary butyl cation is stabilised by the adjacent methyl groups); consequently the lower delta 
positive character of the carbonyl carbon makes entries 4 and 10 (Table 9) less prone to 
undergoing the rearrangement.  More work would needed to done to prove the validity of this 
hypothesis. 
With these results in hand, a further two experiments were conducted to show the usefulness 
of producing these conjugated dienes.  Highly functionalised polycyclic systems are present in 
many drug candidates and biologically active natural products.[78]  The Diels-Alder reaction, 
and in this particular case the intramolecular Diels-Alder (IMDA) reaction, is an attractive 
route towards these fused polycyclic compounds.  Diene 227 (Scheme 82) was used to create 
one such fused polycyclic compound. 
 
 
Scheme 82. Preparation of ester 237 from diene 227 and acryloyl chloride.[79] 
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First, the addition of acryloyl chloride converted the alcohol group to an ester, with the vinyl 
group becoming the ‘dienophile’ for the subsequent IMDA reaction.[79]  The reaction resulted 
in 237 being produced in 85% yield (Scheme 82).  237 was subsequently added to the ionic 
liquid [emim]BF4 (1-ethyl-3-methylimidazolium tetrafluoroborate) and allowed to stir at 
100°C for 6 h.[80]  The IMDA proceeded smoothly, with fused polycyclic system 238 being 
isolated in an excelled 87% yield (Scheme 83).  The stereochemistry was determined through 
NMR spectroscopy, including nOe spectroscopy (Appendix 8.1). 
 
 
Scheme 83. Synthesis of fused polycyclic compound 238 in ionic liquid [emim]BF4.[80] 
 
This shows the usefulness of the chemistry developed here for other applications, not only the 
cross-metathesis reaction proposed in the synthesis of RvE1 that it was originally intended for.  
Conjugated dienes are found in many natural products and drug targets, not only resolvins, and 
therefore it is important to develop new or improve existing synthetic routes towards them.  
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5.0 Future Work 
First and foremost, the most important aspect of future work associated with this project is to 
complete the synthesis of RvE1.  Despite the difficulties in producing the stereogenic centre 
discussed in chapter 4.2.1, the second synthetic route developed towards RvE1 looked 
promising.  There are also several more conditions in the literature that could be trialled in 
order to produce the desired stereochemistry in the alkyne fragment, for example Rodriguez 
and Spur used the Noyori catalyst discussed earlier, along with CTABr as a phase-transfer 
catalyst and sodium formate as the reducing agent.[48]  When these conditions are optimised, 
they can also be applied to the introduction of one of the stereogenic centres in halide fragment.  
Although work had not progressed far through the synthesis of the halide fragment (chapter 
4.2.2), it still shows promise due to the proposed chemistry involving crossover with previously 
successful reactions.  For example, a Sonogashira coupling is proposed to be used, which has 
already been successfully utilised in the synthesis of the original epoxide fragment (chapter 
4.1.2).  The final coupling step of the two fragments is proposed to be a Sonogashira coupling 
also, which should hopefully limit possible issues here also.  Work on the synthesis of RvE1 is 
ongoing in the group, following the second synthetic route outlined at the beginning of chapter 
4.2. 
When the synthetic RvE1 is in hand, work will move on to the biological testing that was the 
driving force for this research project.  Cell cultures of inflammation-induced lung epithelial 
cells will be treated with the synthetic RvE1 and its modified analogues to determine the 
difference in bioactivity.  These analogues are proposed to be produced by modifying the 
synthetic route to give variations in stereochemistry.  For example, the configuration of the 
stereogenic hydroxyl group produced in the alkyne fragment could be reversed by using the R-
enantiomer of the Noyori catalyst, opposed to the S-enantiomer currently being investigated 
(238, Figure 36).  Also, the E C-C double bond set to be introduced in the synthesis of the 
halide fragment by reducing a C-C triple bond with sodium in liquid ammonia could be 
changed to the Z double bond by using Lindlar’s catalyst for the reduction instead (240, Figure 
36). 
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Figure 36.  The structures of RvE1 and potential analogues and fragments of which to test the bioactivity. 
 
Studying the effects of changing stereochemistry on the bioactivity should provide invaluable 
information on which specific aspects of the structure of RvE1 are responsible for its action.  
This will allow for key fragments containing specific functional groups to be identified and 
subsequently tested in order to determine whether the whole structure plays a role in the action 
or just a select few components. 
The same avenue of work could then be used on other members of the resolvin family, both E 
and D series.  New retrosynthetic schemes would have to be developed for each, but the 
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similarities in structures for most would mean that several aspects, such as the introduction of 
stereochemistry, could be transferred from one to another.  These analogues could then be 
tested for bioactivity against those found most potent for RvE1, and hopefully a better 
understanding of how the structure effects action in the resolution of inflammation by resolvins 
can be gained. 
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6.0 Experimental 
6.1 General 
Anhydrous conditions were obtained through the use of oven/flame dried glassware being 
purged with nitrogen prior to the addition of chemical reagents.  A nitrogen atmosphere was 
maintained throughout reactions where necessary through the use of a nitrogen balloon.   
Commercially available solvents were used and not subjected to further purification, except 
THF which was distilled as needed over benzophenone and sodium.  DMSO was purchased 
dry from commercial suppliers.  Light petroleum refers to the fractions with a boiling point 
between 40-60°C.   
NMR spectra were recorded (both 1H and 13C) using either a Bruker 400 MHz or a JEOL 400 
MHz NMR machine.  Chemical shifts are reported in ppm for both forms of spectra.  1H spectra 
were recorded at 400 MHz whereas 13C spectra were recorded at 100 MHz on both machines.  
DEPT was used to assign environment (CH, CH2, CH3) to each carbon atom in the 
13C spectra.  
The solvent system used for NMR spectroscopic measurements is specified with the applicable 
data set.   
NMR nOe spectra were obtained on a Bruker ultra-shield Av-400 spectrometer operating at 
400.13 MHz for protons, employing a 5 mm high-resolution broad-band ATMA gradients 
probe. Spectra were recorded using the selnogp pulse program with P90 = 15.25 μs covering a 
sweep width 20.7 ppm (8278 Hz) with 64k time domain data points giving an acquisition time 
of 3.95 seconds, selective shaped-pulses (Gauss5, 40 ms, 70 dB) were used to irradiate 
individual signals and a mixing time of 0.6 seconds allows nOe enhancements to build-up, 
FIDs were Fourier transformed using 64k data points and referenced to an internal TMS 
standard at 0.0 ppm.  
A Thermofisher Exactive (orbi) mass spectrometer was used to obtain high resolution mass 
spectra, with ESI as the ionisation mode.  The solvent used for all samples was methanol/acetic 
acid. 
A Perkin-Elmer spectrum 65 FT-IR spectrophotometer was used to obtain infrared spectra.  
Spectra obtained from liquid samples were acquired using a thin film on a sodium chloride 
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disc.  Spectra obtained from solid samples were dissolved in a small amount of CH2Cl2 before 
being applied as a thin film on a sodium chloride disc. 
Optical rotation measurements were recorded on an Optical Activity polAAr 2001 automatic 
polarimeter at room temperature.  The solvent system used is specified with the applicable data 
set. 
TLC analysis was carried out on Merck TLC silica gel 60 F254 aluminium backed plates and 
were visualised by vanillin stain or under UV light at 254 nm using a UVP chromato-vue 
cabinet model CC-60. 
Column chromatography used Apollo Scientific ZEOprep 60 silica with a particle size of 40-
63 microns.  The eluent and concentration used is specified with the applicable methods. 
Enantiomeric excess (ee) was determined by chiral HPLC.  A DAICEL CHIRALPAK® IC- 
column was used on a Gilson HPLC instrument attached to a Clarity data station.  Solvent 
system used was hexane:IPA (90:10) with flow rate 0.75 mL.min-1.  
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6.2 Synthetic Procedures 
6.2.1 Synthesis of the RvE1 Lactone Fragment (chapter 4.1.1) 
Diethyl 2-(3-butenyl) malonate[81] 
 
 
 
Sodium (2.5 g, 108 mmol) was added to absolute ethanol (55 mL) and stirred under nitrogen 
at 50°C until complete sodium consumption occurred.  Diethyl malonate (15.2 mL, 100 mmol) 
was added dropwise and the reaction mixture left to stir for 0.5 h. 4-Bromo-1-butene (10.2 mL, 
100 mmol) was added to the reaction mixture and was heated under reflux overnight.  The 
excess ethanol was removed by evaporation under reduced pressure and the product extracted 
with ethyl acetate from distilled water and washed with brine.  The organic extracts were dried 
over magnesium sulfate, filtered and the solvent removed by evaporation under reduced 
pressure.  Excess starting material was removed using bulb-to-bulb distillation yielding the title 
compound as a clear yellow oil (19.50 g, 91 mmol, 91%).  δH (400MHz, CDCl3) 5.70 (tdd, J = 
6.4, 10.4, 16.8 Hz, 1H), 5.00-4.92 (m, 2H), 4.13 (q, J = 7.2 Hz, 4H), 3.29 (t, J = 7.2 Hz, 1H), 
2.03 (q, J = 6.4 Hz, 2H), 1.93, (q, J = 6.4 Hz, 2H), 1.20 (t, J = 7.2 Hz, 6H).  δC (100MHz, 
CDCl3) 169.4, 136.9, 115.9, 61.3, 51.2, 31.3, 27.8, 14.1.  HRMS (ESI) m/z 237.1095 
(C11H18O4Na
+ requires 237.1097).  IR (NaCl) ν 1733, 1642 cm-1. 
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Ethyl 5-hexenoate[81] 
 
 
 
Diethyl 2-(3-butenyl) malonate (10 g, 46 mmol), anhydrous lithium chloride (3.9 g, 92 mmol), 
distilled water (1.65 mL, 92 mmol), and anhydrous DMSO (13 mL, 184 mmol) were stirred 
together at 170°C and allowed to reflux for 48 h.  The product was extracted once with diethyl 
ether and then subsequently by ethyl acetate, from distilled water and washed with brine.  The 
organic extracts were dried over magnesium sulfate, filtered and the solvent removed by 
evaporation under reduced pressure yielding a brown liquid.  The title compound was isolated 
by column chromatography (9:1, light petroleum: ethyl acetate, Rf = 0.8) yielding a colourless 
liquid (5.26 g, 37 mmol, 80%).  δH (400MHz, CDCl3) 5.79 (tdd, J = 6.8, 10.0, 17.2 Hz, 1H), 
5.08-4.95 (m, 2H), 4.13 (q, J = 7.2 Hz, 2H), 2.32 (t, J = 7.6 Hz, 2H), 2.10 (q, J = 7.2 Hz, 2H), 
1.74 (quin, J = 7.2 Hz, 2H), 1.27 (t, J = 7.0 Hz, 3H).  δC (100MHz, CDCl3) 173.7, 137.7, 115.3, 
60.2, 33.2, 32.9, 24.1, 14.2.  HRMS (ESI) m/z 165.0884 (C8H14O2Na
+ requires 165.0886).  IR 
(NaCl) ν 1735, 1641 cm-1. 
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Dimethyl 2-(3-butenyl) malonate[82] 
 
 
 
Sodium (0.7 g, 30 mmol) was added to methanol (12 mL) and stirred under nitrogen at 50°C 
until complete sodium consumption occurred.  Dimethyl malonate (5 mL, 44 mmol) was added 
dropwise and the reaction mixture left to stir for 0.5 h. 4-Bromo-1-butene (3 mL, 30 mmol) 
was added to the reaction mixture and was heated under reflux overnight.  The excess methanol 
was removed by evaporation under reduced pressure and the product extracted with ethyl 
acetate from distilled water and washed with brine.  The organic extracts were dried over 
magnesium sulfate, filtered and the solvent removed by evaporation under reduced pressure.  
Excess starting material was removed using bulb-to-bulb distillation yielding the title 
compound as a clear yellow oil (4.58 g, 24.6 mmol, 82%).  The data are consistent with that in 
literature.[82]  δH (400MHz, CDCl3) 5.72 (tdd, J = 6.4, 10.4, 16.8 Hz, 1H), 5.02-4.94 (m, 2H), 
3.65 (s, 6H), 3.31 (t, J = 7.2 Hz, 1H), 2.05 (q, J = 6.4 Hz, 2H), 1.95 (q, J = 6.4 Hz, 2H). 
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Methyl 5-hexenoate[83] 
 
 
 
Dimethyl 2-(3-butenyl) malonate (0.186 g, 1 mmol), sodium chloride (0.117 g, 2 mmol), 
distilled water (0.04 mL, 2 mmol), and anhydrous DMSO (0.28 mL, 4 mmol) were stirred 
together at 150°C and allowed to reflux overnight.  The product was extracted with ethyl 
acetate from distilled water and washed with brine.  The organic extracts were dried over 
magnesium sulfate, filtered and the solvent removed by evaporation under reduced pressure 
yielding a brown liquid.  The title compound was isolated by column chromatography (9:1, 
light petroleum: ethyl acetate, Rf = 0.8) yielding a colourless liquid (4 mg, 0.03 mmol, 3%).  
%).  The data are consistent with that in literature.[83]  δH (400MHz, CDCl3) 5.83 (tdd, J = 6.8, 
10.0, 17.2 Hz, 1H), 5.05-4.94 (m, 2H), 3.61 (s, 3H), 2.36 (t, J = 7.6 Hz, 2H), 2.18 (q, J = 7.2 
Hz, 2H), 1.88 (quin, J = 7.2 Hz, 2H).  
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Ethyl 5,6-epoxyhexanoate[53] 
 
 
 
Ethyl 5-hexenoate (3.50 g, 25 mmol) was added to dichloromethane (100 mL) and meta-
chloroperoxybenzoic acid (6.16 g, 25 mmol, 70%).  The reaction mixture was left to stir 
overnight at room temperature then diluted with ethyl acetate and washed with brine, saturated 
Na2S2O3 solution, and saturated NaHCO3 solution.  The organic extracts were dried over 
magnesium sulfate, filtered and the solvent removed by evaporation under reduced pressure 
yielding a yellow oil with some white precipitate.  The title compound was isolated by column 
chromatography (9:1, light petroleum: ethyl acetate, Rf = 0.6) yielding a pale yellow oil (3.12 
g, 20 mmol, 79%).  δH (400MHz, CDCl3) 4.07 (q, J = 7.2 Hz, 2H), 2.87-2.82 (m, 1H), 2.68 (t, 
J = 4.4 Hz, 1H), 2.40 (dd, J = 2.8, 4.8 Hz, 1H), 2.30 (t, J = 7.2 Hz, 2H), 1.81-1.66 (m, 2H), 
1.60-1.43 (m, 2H), 1.19 (t, J = 7.2 Hz, 3H).  δC (100MHz, CDCl3) 173.3, 60.3, 51.8, 46.9, 33.9, 
31.8, 21.4, 14.2.  HRMS (ESI) m/z 181.0833 (C8H14O3Na
+ requires 181.0835).  IR (NaCl) ν 
2982, 1733 cm-1. 
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(R,R)-(-)-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminocobalt(III) 
tosylate[57] 
 
 
 
(R,R)-(-)-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminocobalt(II) (0.61 g, 1 
mmol) and p-toluenesulfonic acid monohydrate (0.20 g, 1.05 mmol) were added together in 
dichloromethane (30 mL) and stirred open to air overnight.  Excess solvent was removed under 
reduced pressure and the resulting solid was dried under reduced pressure for a further 5 h.  
The resulting solid was suspended in hexane and the precipitate filtered yielding a green solid 
(0.76 g, 0.98 mmol, 98%).  The data are consistent with that in the literature.[57]  δH (400MHz, 
CDCl3) 8.31 (s, 1H), 7.74 (m, 2H), 7.52 (m, 2H), 7.48 (m, 2H), 7.40 (m, 2H), 3.25 (t, J = 11.2 
Hz, 2H), 2.34 (s, 3H), 2.19 (m, 2H), 1.94 (m,2H), 1.66 (m, 2H), 1.56 (m, 2H), 1.35 (s, 12H).  
HRMS (ESI) m/z 797.3365 (CoC43H59N2O5SNa
+ requires 797.3369).  m.p. >350°C.   
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(R,R)-(-)-N,N’-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminocobalt(III) 
acetate[57] 
 
 
 
Cobalt(II) acetate (0.71 g, 4.02 mmol) and (R,R)-(+)-N,N’-bis(3,5-di-tert-butylsalicylidene)-
1,2-cyclohexanediamine (2 g, 3.66 mmol) were added to glacial acetic acid (25 mL) and stirred 
open to air overnight at room temperature.  Solvent was removed by evaporation under reduced 
pressure yielding the crude product as a black solid.  This was dissolved in methanol and stirred 
rapidly for 0.5 h.  Distilled water was then added dropwise causing the title compound to 
precipitate.  The suspension was added to a centrifuge which enabled the title product to be 
isolated as a fine brown powder (2.13 g, 3.22 mmol, 88%).  The data are consistent with that 
in the literature.[57]  δH (400MHz, CDCl3) 7.51 (s, 2H), 7.46-7.35 (m, 4H), 2.82-2.72 (m, 2H), 
1.86 (s, 3H), 1.36 (s, 18H), 1.30 (s, 18H), 1.29-0.96 (m, 8H).  HRMS (ESI) m/z 685.3375 
(CoC38H55N2O4Na
+ requires 685.3386).  m.p >350°C. 
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Hydrolytic kinetic resolution of ethyl 5,6-epoxyhexanoate[53] 
Racemic ethyl 5,6-epoxyhexanoate (4.9 g, 31 mmol) was added to (R,R)-(+)-N,N’-bis(3,5-di-
tert-butylsalicylidene)-1,2-cyclohexanediaminocobalt(III) acetate (0.11 g, 0.155 mmol) and 
distilled water (0.39 mL, 21 mmol).  The reaction mixture was sealed and allowed to stir at 
room temperature overnight.  The reaction mixture was diluted with distilled water before the 
products were extracted with ethyl acetate.  The organic extracts were dried over magnesium 
sulfate, filtered and the solvent removed by evaporation under reduced pressure yielding a 
yellow oil.  The two reaction products were separated and isolated by column chromatography 
(2:1, light petroleum: ethyl acetate, Rf (124) = 0.8, Rf (123) = 0.2). 
 Ethyl (R)-(+)-5,6-epoxyhexanoate 
 
 
 
The title compound was isolated as a pale yellow oil (2.21 g, 13.95 mmol, 45% yield, 98.2% 
ee).  δH (400MHz, CDCl3) 4.07 (q, J = 7.2 Hz, 2H), 2.85 (dddd, J = 2.8, 4.0, 4.8, 6.4 Hz, 1H), 
2.68 (dd, J = 4.0, 5.2 Hz, 1H), 2.41 (dd, J = 2.8, 5.2, Hz, 1H), 2.30 (t, J = 7.2 Hz, 2H), 1.80-
1.67 (m, 2H), 1.58-1.51 (m, 2H), 1.19 (t, J = 7.2 Hz, 3H).  δC (100MHz, CDCl3) 173.3, 60.3, 
51.8, 46.9, 33.9, 31.8, 21.4, 14.2.  HRMS (ESI) m/z 181.0832 (C8H14O3Na
+ requires 181.0835).  
IR (NaCl) 2983, 1733 cm-1.  [α]𝟐𝟎
ᴅ
 = +15.8° (c 1.0, CHCl3), lit. [α]
𝟐𝟎
ᴅ
 = +14.9° (c 0.2, CHCl3).
[53]  
Chiral HPLC (Chiracel 1C column, hexane:IPA = 9:1) showed 98.2% ee (t1 = 19.60 min 
(major), t2 = 23.68 min (minor)). 
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 Ethyl (S)-(-)-5,6-dihydroxyhexanoate[53] 
 
 
 
The title compound was isolated as a brown oil (1.04 g, 5.89 mmol, 19% yield, 81.6% ee).  δH 
(400MHz, CDCl3) 4.07 (q, J = 7.2 Hz, 2H), 3.69-3.56 (m, 2H), 3.44-3.36 (m, 1H), 2.38 (br s, 
1H), 2.28 (t, J = 7.2 Hz, 2H), 2.04 (br s, 1H), 1.78-1.59 (m, 2H), 1.41 (q, J = 7.6 Hz, 2H), 1.19 
(t, J = 7.2 Hz, 3H).  δC (100MHz, CDCl3) 173.8, 71.6, 66.6, 60.4, 34.0, 32.6, 20.7, 14.2.  HRMS 
(ESI) m/z 199.0939 (C8H16O4Na
+ requires 199.0941).  IR (NaCl) 3502 (br), 1737.  [α]𝟐𝟎
ᴅ
 = -
28.0° (c 1.0, EtOH), lit. [α]𝟐𝟎
ᴅ
 = -14.1° (c 2.0, EtOH).[53]  Chiral HPLC (Chiracel 1C column, 
hexane:IPA = 9:1) showed 81.6% ee (t1 = 11.81 min (major), t2 = 16.20 min (minor)). 
  
126 
 
(S)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2-one[53] 
 
 
 
A solution of ethyl (S)-(-)-5,6-epoxyhexanoate (316 mg, 2 mmol) and LiOH.H2O (252 mg, 6 
mmol) in MeOH:H2O (1:1, 10 mL) was stirred under reflux for 3 h.  The solution was then 
acidified using concentrated HCl to approximately pH 4 and the product extracted with ethyl 
acetate.  The organic extracts were dried over magnesium sulfate, filtered, and the solvent 
removed by evaporation under reduced pressure.  The resulting crude product was stirred in 
dichloromethane (10 mL) and to it was added CSA (46 mg, 0.2 mmol).  After stirring at -5°C 
for 20 minutes the reaction was quenched with Et3N, which was subsequently removed along 
with the solvent by evaporation under reduced pressure.  The title compound was isolated by 
column chromatography (9:1, light petroleum: ethyl acetate, Rf = 0.1) yielding a colourless oil 
(127 mg, 0.98 mmol, 49%).  δH (400MHz, CDCl3) 4.49 (ddt, J = 3.6, 4.8, 10.8 Hz, 1H), 3.61 
(d, J = 4.8 Hz, 2H), 2.60-2.52 (m, 1H), 2.46-2.36 (m, 1H), 2.03-1.95 (m, 1H), 1.95-1.87 (m, 
1H), 1.87-1.77 (m, 1H), 1.73-1.63 (m, 1H).  δC (100MHz, CDCl3) 170.7, 78.9, 46.0, 29.6, 25.3, 
18.2.  HRMS (ESI) m/z 153.0520 (C6H10O3Na
+ requires 153.0522).  IR (NaCl, in CH2Cl2) 3418 
(br), 1735, 1165 cm-1.  [α]𝟐𝟎
ᴅ
 = +33.8° (c 1.0, CHCl3), lit. [α]
𝟐𝟎
ᴅ
 = +34.5° (c 0.6, CHCl3).
[53] 
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6.2.2 Synthesis of the RvE1 Epoxide Fragment (chapter 4.1.2) 
2,3-O-Isopropylidene-D-glyceraldehyde[59] 
 
 
 
1,2:5,6-Diisopropylidene-D-mannitol (5.00 g, 19 mmol) was added to dichloromethane (50 
mL) and stirred for 10 minutes.  Saturated NaHCO3 (2 mL, 2.29 mmol) was added followed 
by sodium metaperiodate (8.17 g, 38 mmol) slowly over 5 minutes whilst ensuring that the 
reaction temperature does not exceed 35°C using water bath cooling.  The reaction mixture 
was then stirred at room temperature for 2 h before magnesium sulfate (2.5 g) was added and 
stirring continued for 20 minutes.  The reaction mixture was then filtered and the filtrate 
retained.  The filter cake was added to dichloromethane (50 mL) and stirred for 10 minutes 
before being filtered again.  The filter cake was discarded and the filtrate added to that collected 
previously.  Solvent was removed by evaporation under reduced pressure yielding the title 
compound as a thick, clear oil (4.29 g, 33 mmol, 87%).  δH (400MHz, CDCl3) 9.65 (d, J = 2.0 
Hz, 1H), 4.32 (ddd, J = 2.0, 4.8, 8.0 Hz, 1H), 4.11 (t, J = 8.0 Hz, 1H), 4.05 (d, J = 4.8 Hz, 1H), 
1.42 (s, 3H), 1.36 (s, 3H).  δC (100MHz, CDCl3) 201.9, 120.7, 100.8, 65.6, 26.3, 25.3.  HRMS 
(ESI) m/z 153.0519 (C6H10O3Na
+ requires 153.0522).  IR (NaCl) 1736, 1220 cm-1.  [α]𝟐𝟑
ᴅ
 = 
+87.5°   (c 1.0, CHCl3), lit. [α]
𝟐𝟑
ᴅ
 = between +70° and +80° (c 1.0-1.5, CHCl3).
[59] 
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Ethyl (S,E)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)acrylate[60] 
 
 
 
2,3-O-Isopropylidene-D-glyceraldehyde (0.5 g, 3.84 mmol) was added to methanol (25 mL) at 
0°C.  (Carbethoxymethylene)triphenylphosphorane (1.3 g, 3.73 mmol) was added and the 
reaction mixture stirred at 0°C for 2 h.  The solvent was removed by evaporation under reduced 
pressure yielding a colourless liquid and some white precipitate.  This was added to a mixture 
of diethyl ether: hexane (3:7) and heated to reflux for 30 minutes.  The solvent was decanted 
and collected whilst the remaining solid was added for further diethyl ether: hexane mix and 
heated to reflux for a further 30 minutes.  This process was repeated a further 3 times.  The 
remaining solid residue was discarded and the solvent removed from the cooled extracts by 
evaporation under reduced pressure yielding the crude product.  The title compound was 
isolated by column chromatography (9:1, light petroleum: ethyl acetate, Rf = 0.4) yielding a 
colourless liquid (0.537 g, 2.68 mmol, 72%).  The data are consistent with that in the 
literature.[60]  δH (400MHz, CDCl3) 6.80 (dd, J = 5.6, 15.6 Hz, 1H), 6.02 (d, J = 15.6 Hz, 1H), 
5.50 (ddd, J = 2.0, 6.8, 8.0 Hz, 1H), 4.39 (dd, J = 6.8, 8.0 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 
3.63 (dd, J = 6.8, 8.0 Hz, 1H), 1.46 (s, 3H), 1.40 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H).  [α]𝟐𝟑
ᴅ
 = 
+40.5° (c 1.0, CHCl3), lit. [α]
𝟐𝟑
ᴅ
 = +38° (c 1.0, CHCl3).
[60]  
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Triphenyl(3-(trimethylsilyl)prop-2-yn-1-yl)phosphonium bromide[84] 
  
 
 
3-Bromo-1-trimethylsilyl-1-propyne (2.5 g, 13 mmol) was added to triphenylphosphine (3.75 
g, 14 mmol) in toluene (30 mL) and stirred at room temperature for 18 h in darkness.  The 
reaction mixture was filtered under vacuum and the precipitate washed with light petroleum 
before being dried under reduced pressure for 7 h.  Recrystallisation was found to decompose 
the product, therefore only the crude product could be isolated as a brown solid (4.58 g, 10 
mmol, 78%).  The data are consistent with that in the literature.[84]  δH (400MHz, CDCl3) 8.00-
7.71 (m, 15H), 5.30 (s, 2H), 0.00 (s, 9H).  m.p 155.9 – 157.8°C, lit 154 - 156°C.[84] 
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β-Iodostyrene[61] 
 
 
 
Anhydrous chromium(II) chloride (0.74 g, 6 mmol) was suspended in dry THF (10 mL) under 
nitrogen and stirred for 10 minutes.  A solution of benzaldehyde (0.11 g, 1 mmol) and iodoform 
(0.79 g, 2 mmol) in dry THF (5 mL) was added dropwise at 0°C and was allowed to stir 
overnight at room temperature.  The reaction mixture was added to distilled water and the 
product extracted with diethyl ether.  The organic extracts were dried over magnesium sulfate, 
filtered, and the solvent removed by evaporation under reduced pressure.  Column 
chromatography (light petroleum) was used to isolate the title compound as a yellow solid (0.23 
g, 0.93 mmol, 99%).  The data are consistent with that in the literature.[61]  δH (400MHz, CDCl3) 
7.43 (d, J = 15.2 Hz, 1H), 7.33-7.27 (m, 5H), 6.83 (d, J = 14.8 Hz, 1H). 
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(S,E)-4-(2-iodovinyl)-2,2-dimethyl-1,3-dioxolane[61] 
 
 
 
Anhydrous chromium(II) chloride (0.74 g, 6 mmol) was suspended in dry THF (10 mL) under 
nitrogen and stirred for 10 minutes.  A solution of 2,3-O-isopropylidene-D-glyceraldehyde 
(0.13 g, 1 mmol) and iodoform (0.79 g, 2 mmol) in dry THF (5 mL) was added dropwise at 
0°C and was allowed to stir overnight at room temperature.  The reaction mixture was added 
to distilled water and the product extracted with diethyl ether.  The organic extracts were dried 
over magnesium sulfate, filtered, and the solvent removed by evaporation under reduced 
pressure.  Column chromatography was found to decompose the product, therefore only the 
crude mixture could be isolated as wet, yellow solid (0.31 g, 1.22mmol, 122%). δH (400MHz, 
CDCl3) 6.59-6.39 (m, 2H), 4.49 (q, J = 6.0 Hz, 1H), 4.11 (dd, J = 6.4, 8.4 Hz, 1H), 3.68-3.62 
(m, 1H), 1.43 (s, 3H), 1.38 (s, 3H). δC (100MHz, CDCl3) 144.3, 120.6, 91.7, 79.3, 65.6, 25.9, 
25.8. HRMS (ESI) m/z 277.0566 (M+H) (C7H11O2INa
+ requires 277.0567 (M+H)). IR (NaCl) 
1641, 1267, 562 cm-1.  [α]𝟐𝟑
ᴅ
 = -21.8° (c 1.0, EtOH). 
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Recrystallisation of copper(I) iodide[85] 
Crude copper(I) iodide was dissolved in boiling saturated aqueous sodium iodide solution and 
allowed to stir for 0.5 h.  The mixture was cooled to room temperature and diluted with distilled 
water, absolute ethanol, ethyl acetate, hexane and diethyl ether.  The precipitate was filtered 
and dried under reduced for 24 hours yielding pure copper(I) iodide. 
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(4S)-2,2-Dimethyl-4-(4-trimethylsilylbut-1-en-3-ynyl)-l,3-dioxolane[86] 
 
 
 
Crude (S,E)-4-(2-iodovinyl)-2,2-dimethyl-1,3-dioxolane (0.96 g, 4.2 mmol), Pd(PPh3)2Cl2 
(0.15 g, 0.21 mmol), copper iodide (0.08 g, 0.42 mmol), and piperidine (12.4 mL, 126 mmol) 
were added together and stirred under nitrogen for 10 minutes.  Ethynyltrimethylsilane (0.89 
g, 6.3 mmol) was added and the reaction mixture was allowed to stir for 2 h.  Saturated aqueous 
NH4Cl was added at 0°C in order to quench the reaction and the product extracted with diethyl 
ether.  The organic extracts were dried over magnesium sulfate, filtered, and the solvent 
removed by evaporation under reduced pressure yielding a brown solid.  The title compound 
was isolated by column chromatography (graduated, 95:5-50:50, light petroleum: diethyl ether.  
Rf = 0.4 (9:1)) yielding a yellow oil (0.65 g, 2.89 mmol, 69%).  δH (400Mz, CDCl3) 5.95 (dd, 
J = 6.8, 16.0 Hz, 1H), 5.61 (dd, J = 1.2, 16.0 Hz, 1H), 4.37-4.30 (m, 1H), 3.92 (dd, J = 6.4, 8.4 
Hz, 1H), 3.43 (dd, J = 7.2, 8.4 Hz, 1H), 1.23 (s, 3H), 1.19 (s, 3H), 0.00 (s, 9H).  δC (100Mz, 
CDCl3) 141.5, 112.6, 106.6, 102.8, 96.2, 79.3, 69.3, 23.0, 22.9, 0.1.  HRMS (ESI) m/z 248.1193 
(C12H20O2SiNa
+ requires 248.1188).  IR (NaCl) 2180, 1641, 1251 cm-1.  [α]𝟐𝟑
ᴅ
 = -20.5° (c 1.0, 
EtOH), lit. [α]𝟐𝟑
ᴅ
 = -23° (c 1.837, EtOH).[84] 
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(S,E)-6-(Trimethylsilyl)hex-3-en-5-yne-1,2-diol 
 
 
 
(4S)-2,2-Dimethyl-4-(4-trimethylsilybut-1-en-3-ynyl)-1,3-dioxolane (1.82 g, 8.11 mmol), 2 M 
HCl (9.35 mL) and absolute ethanol (26 mL) were added together and the reaction mixture was 
allowed to stir at room temperature for 5 h.  The reaction mixture was quenched by the addition 
of sodium bicarbonate.  The insoluble material was filtered and the solvent removed by 
evaporation under reduced pressure yielding a brown liquid.  The title compound was isolated 
by column chromatography (2:1, light petroleum: ethyl acetate, Rf = 0.1) yielding a colourless 
oil (1.48 g, 8.04 mmol, 98%).  δH (400MHz, CDCl3) 5.99 (dd, J = 5.6, 16.8 Hz, 1H), 5.67 (dd, 
J = 1.6, 16.0 Hz, 1H), 4.15-4.09 (m, 1H), 3.50 (dd, J = 3.6, 11.6 Hz, 1H), 3.32 (dd, J = 7.2, 11.6 
Hz, 1H), 0.00 (s, 9H).  δC (100MHz, CDCl3) 142.3, 112.0, 102.8, 96.2, 72.6, 66.1, 0.0.  HRMS 
(ESI) m/z 207.0808 (C9H16O2SiNa
+ requires 207.0812).  IR (NaCl) ν 3428 (br), 2179, 1638   
cm-1.  [α]𝟐𝟎
ᴅ
 = -31.8° (c 1.0, EtOH). 
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(S,E)-2,2-Dimethyl-4-styryl-1,3-dioxolane[87] 
 
 
 
To a suspension of [PPh3CH2Ph]Br (2.14 g, 4.95 mmol) in anhydrous THF (10 mL) under 
nitrogen atmosphere, was added nBuLi (3.12 mL, 5 mmol) at 0°C and stirred for 15 minutes.  
A solution of 2,3-O-isopropylidene-D-glyceraldehyde (0.65 g, 5 mmol) in anhydrous THF (2 
mL) was added dropwise and allowed to stir at 0°C for an additional 1 h.  The reaction mixture 
was then quenched with saturated NH4Cl and extracted with diethyl ether.  The organic extracts 
were then washed with brine before being dried over magnesium sulfate and filtered.  The 
solvent was removed by evaporation under reduced pressure.  The title compound was isolated 
by column chromatography (9:1, light petroleum: ethyl acetate, Rf = 0.6) yielding a pale yellow 
oil (0.91 g, 4.45 mmol, 89%).  The data are consistent with that in the literature.[87]  δH 
(400MHz, CDCl3) 7.51-7.45 (m, 5H), 6.73 (d, J = 16.0 Hz, 1H), 5.72 (dd, J = 9.2, 16.0 Hz, 
1H), 4.96-4.91 (m, 1H), 3.71 (t, J = 8.0 Hz, 1H), 3.69 (t, J = 8.0 Hz, 1H), 1.49 (s, 3H), 1.40 (s, 
3H). 
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(S,E)-4-Phenylbut-3-ene-1,2-diol 
 
 
 
(S,E)-2,2-Dimethyl-4-styryl-1,3-dioxolane (0.48 g, 2.34 mmol), 2 M HCl (2.44 mL) and 
absolute ethanol (7 mL) were added together and the reaction mixture was allowed to stir at 
room temperature for 5 h.  The reaction mixture was quenched by the addition of sodium 
bicarbonate.  The insoluble material was filtered and the solvent removed by evaporation under 
reduced pressure yielding a brown solid.  The title compound was isolated by column 
chromatography (2:1, light petroleum: ethyl acetate, Rf = 0.1) yielding a pale yellow solid (0.37 
g, 2.25 mmol, 96%).  The data are consistent with that in the literature.[88]  δH (400MHz, CDCl3) 
7.61-7.49 (m, 5H), 6.60 (d, J = 16.0 Hz, 1H), 5.68 (dd, J = 9.2, 16.0 Hz, 1H), 4.73-4.68 (m, 
1H), 3.72 (dd, J = 3.2, 11.2 Hz, 1H), 3.60 (dd, J = 8.0, 11.6 Hz, 1H), 2.99 (br s, 1H), 2.80 (br 
s, 1H). m.p. 54.9 – 56.4°C, lit. 55 – 57°C.[88] 
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(S,E)-4-Styryl-1,3,2-dioxathiolane 2,2-dioxide 
 
 
 
(S,E)-4-Phenylbut-3-ene-1,2-diol (1.18 g, 6.4 mmol) in anhydrous chloroform (8 mL) was 
stirred in flame dried glassware at room temperature under a nitrogen atmosphere.  To it thionyl 
chloride (0.55 mL, 7.7 mmol) was added dropwise, followed by the addition of triethylamine 
(0.89 mL, 6.4 mmol).  The reaction mixture was heated to reflux and allowed to stir for 1 h.  
The reaction mixture was then cooled to room temperature and to it was added a solution of 
RuCl3.xH2O (0.13 g, 0.64 mmol), NaIO4 (2.05 g, 9.6 mmol), acetonitrile (8 mL) and distilled 
water (10 mL).  After stirring for 1.5 h, the resulting mixture was diluted with diethyl ether and 
washed with distilled water, saturated aqueous NaHCO3.  The organic extracts were dried over 
magnesium sulfate, filtered, and the solvent removed by evaporation under reduced pressure.   
The title compound was isolated by column chromatography (9:1, light petroleum: ethyl 
acetate, Rf = 0.4) yielding a dark yellow oil (0.06 g, 0.3 mmol, 4%).   δH (400MHz, CDCl3) 
7.64-7.41 (m, 5H), 6.76 (d, J = 16.0 Hz, 1H), 6.23 (dd, J = 9.2, 16.0 Hz, 1H), 5.38-5.31 (m, 
1H), 4.86 (t, J = 8.0 Hz, 1H), 4.53 (t, J = 8.0 Hz, 1H).  δC (100MHz, CDCl3) 138.1, 130.2, 
129.7, 128.0. 126.5, 125.4, 81.3, 70.3.  HRMS (ESI) m/z 249.0190 (C10H10O4SNa
+ requires 
249.0192).  IR (NaCl) ν 3028, 1645, 1411, 1192 cm-1. 
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6.2.3 Synthesis of the RvE1 Alkyne Fragment (chapter 4.2.1) 
Methyl 5-oxo-7-(trimethylsilyl)hept-6-ynoate 
 
 
 
A solution of aluminium chloride (1.86 g, 14 mmol) in dichloromethane (15 mL) was stirred 
at -15°C.  To is was added dropwise a solution of bis(trimethylsilyl)acetylene (2.18 g, 13 
mmol), and glutaric acid methyl ester chloride (1.6 mL, 12 mmol) in dichloromethane (20 mL).  
The reaction mixture was allowed to stir at -15°C for 1 h before being quenched with ice and 
saturated aqueous citric acid.  The product was then extracted with diethyl ether and organic 
extracts washed with brine before being dried over magnesium sulfate and filtered.  The solvent 
was removed by evaporation under reduced pressure.  The title compound was isolated by 
column chromatography (4:1, light petroleum: ethyl acetate, Rf = 0.6) yielding a pale yellow 
oil (1.9 g, 8.4 mmol, 70%).  δH (400MHz, CDCl3) 3.69 (s, 3H), 2.67 (t, J = 7.2 Hz, 2H), 2.39 
(t, J = 7.2 Hz, 2H), 1.99 (quin, J = 7.2 Hz, 2H), 0.25 (s, 9H).  δC (100MHz, CDCl3) 186.7, 
173.3, 101.8, 98.1, 51.6, 44.3, 33.3, 18.9, 1.3.  HRMS (ESI) m/z 249.0917 (C11H18O3SiNa
+ 
requires 249.0915).  IR (NaCl) ν 2092, 1738, 1679 cm-1. 
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Reduction of the ketone of methyl 5-oxo-7-(trimethylsilyl)hept-6-ynoate with NaBH4 
Methyl 5-oxo-7-(trimethylsilyl)hept-6-ynoate (0.1 g, 0.44 mmol) was added to anhydrous THF 
(1 mL) and stirred under nitrogen at -78°C.  1 M DIBAL-H in THF (0.44 mL) was added 
dropwise and the reaction mixture allowed to stir for 0.5 h.  The reaction mixture was quenched 
with methanol, followed by distilled water, before the product was extracted into diethyl ether.  
The organic extracts were dried over magnesium sulfate and filtered, before the solvent was 
removed by evaporation under reduced pressure.  The two reaction products were separated 
and isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf (171) = 0.9, Rf 
(166) = 0.3). 
 Methyl 5-hydroxy-7-(trimethylsilyl)hept-6-ynoate 
 
 
 
The title compound was isolated as a pale yellow oil (30 mg, 0.13 mmol, 30%).  δH (400MHz, 
CDCl3) 4.24-4.20 (m, 1H), 3.66 (s, 3H), 2.77 (t, J = 8.0 Hz, 2H), 2.03 (s, 1H), 1.89-1.61 (m, 
4H), 0.15 (s, 9H).  δC (100MHz, CDCl3) 173.4, 104.5, 92.2, 66.8, 51.8, 44.4, 32.7, 21.6, 0.2.  
HRMS (ESI) m/z 227.3555 (M-H) (C11H20O3Si requires 227.3554 (M-H).  IR (NaCl) ν 3350 
(br), 2180, 1741, 1252 cm-1. 
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 6-((Trimethylsilyl)ethynyl)tetrahydro-2H-pyran-2-one 
 
 
 
The title compound was isolated as a pale yellow oil (37 mg, 0.19 mmol, 43%).  δH (400MHz, 
CDCl3) 4.14 (t, J = 6.4 Hz, 1H), 2.40 (t, J = 7.0 Hz, 2H), 1.89-1.72 (m, 4H), 0.19 (s, 9H).  δC 
(100MHz, CDCl3) 173.5, 106.3, 88.6, 63.3, 36.9, 33.8, 19.1, 0.1.  HRMS (ESI) m/z 219.3107 
(C10H16O2SiNa
+ requires 219.3102).  IR (NaCl) ν 2180, 1740, 1251 cm-1. 
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6.2.4  Synthesis of the RvE1 Halide Fragment (chapter 4.2.2) 
1,4-Pentadien-3-ol[71] 
 
 
 
1M Vinyl magnesium bromide in dry THF (50.97 mL, 50 mmol) was stirred under nitrogen at 
0°C.  Ethyl formate (2.02 mL, 25 mmol) was added dropwise over 1 h whilst maintaining the 
reaction temperature remained below 15°C.  The reaction mixture was stirred for a further 1 h 
at room temperature before being quenched by the addition of saturated aqueous NH4Cl 
solution.  The organic layer was separated and the aqueous layer extracted twice by diethyl 
ether.  The organic extracts were combined and washed further with brine and saturated 
aqueous NH4Cl before being dried over magnesium sulfate, filtered and the solvent removed 
by evaporation under reduced pressure yielding a colourless liquid.  The title compound was 
isolated by bulb-to-bulb distillation as a colourless liquid (1.49 g, 17.71 mmol, 71%).  δH 
(400MHz, CDCl3) 5.90 (ddd, J = 5.6, 10.4, 16.8 Hz, 2H), 5.29 (d, J = 16.8 Hz, 2H), 5.17 (d, J 
= 10.4 Hz, 2H), 4.64 (t, J = 5.6 Hz, 1H), 2.16 (br s, 1H).  δC (100MHz, CDCl3) 139.2, 115.3, 
73.9.  HRMS (ESI) m/z 107.0470 (C5H8ONa
+ requires 107.0473).  IR (NaCl) ν 3352 (br), 3083, 
1638 cm-1. 
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(E)-5-Bromopenta-1,3-diene[71] 
 
 
 
1,4-Pentadien-3-ol (1 g, 11.89 mmol) was cooled to -15°C and allowed to stir.  48% Hydrogen 
bromide solution (0.78 mL, 14.27 mmol) was added dropwise over 1 h and the reaction mixture 
allowed to stir at -15°C for a further 1 h.  The organic layer was separated and washed with 
distilled water before the title compound was isolated by bulb-to-bulb distillation yielding a 
yellow oil (1.15 g, 7.82 mmol, 66%).  δH (400MHz, CDCl3) 6.43-6.25 (m, 2H), 5.88 (td, J = 
6.0, 15.2 Hz, 1H), 5.25 (d, J = 15.2 Hz, 1H), 5.13 (d, J = 8.8 Hz, 1H), 4.22 (d, J = 6.0 Hz, 2H).  
δC (100MHz, CDCl3) 135.5, 135.3, 129.1, 119.5, 32.9.  HRMS (ESI) m/z 147.9705 (C5H7Br 
requires 147.9715).  IR (NaCl) 3088, 653 cm-1. 
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3-Vinylpent-4-ene-1,2-diol 
 
 
 
Glycolaldehyde dimer (0.75 g, 6.24 mmol) and (E)-5-bromopenta-1,3-diene (2.20 g, 14.99 
mmol) were added to absolute ethanol (2.2 mL) and allowed to stir at room temperature.  
Indium powder (2.15 g, 18.73 mmol) was added slowly, so as not to increase the temperature 
of the reaction mixture, and then allowed to stir at room temperature for 72 h.  The reaction 
mixture was diluted with diethyl ether and then filtered through a plug of silica.  The solvent 
was removed by evaporation under reduced pressure.  The title compound was isolated by 
column chromatography (2:1, light petroleum: ethyl acetate, Rf = 0.2) yielding a colourless 
liquid (1.15 g, 12.48 mmol, 72%).  δH (400MHz, CDCl3) 5.86 (ddd, J = 8.0, 10.8, 16.8 Hz, 1H), 
5.77 (ddd, J = 8.0, 10.8, 16.8 Hz, 1H), 5.21-5.11 (m, 4H), 3.71-3.62 (m, 2H), 3.55-3.47 (m, 
1H), 3.23 (s, 1H), 3.15 (s, 1H), 2.88 (q, J = 8.0 Hz, 1H).  δC (100MHz, CDCl3) 136.8, 136.7, 
117.5, 117.1, 73.6, 64.6, 51.7.  HRMS (ESI) m/z 151.0729 (C7H12O2Na
+ requires 151.0730).  
IR (NaCl) ν 3365 (br), 3003, 1637 cm-1. 
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1-((tert-Butyldiphenylsilyl)oxy)-3-vinylpent-4-en-2-ol 
 
 
 
3-Vinylpent-4-ene-1,2-diol (100 mg, 0.78 mmol) was added to a round-bottomed flask at 0°C 
and flushed with nitrogen.  A mixture of tert-butyldiphenylchlorosilane (214 mg, 0.78 mmol) 
and imidazole (106 mg, 1.56 mmol) in dichloromethane (3.12 mL) was added dropwise and 
the reaction mixture allowed to stir at 0°C overnight.  Saturated aqueous NH4Cl was added to 
the reaction mixture and the product extracted with diethyl ether.  The organic extracts were 
washed with brine and then dried over magnesium sulfate, filtered and the solvent removed by 
evaporation under reduced pressure.  The title compound was yielded as a thick, colourless oil 
(233 mg, 0.64 mmol, 81%).  δH (400MHz, CDCl3) 7.71-7.66 (m, 4H), 7.49-7.39 (m, 6H), 5.91 
(ddd, J = 7.6, 10.0, 17.2 Hz, 1H), 5.76 (ddd, J = 8.0, 13.2, 17.6 Hz, 1H), 5.18-5.06 (m, 2H), 
3.75-3.69 (m, 2H), 3.67-3.61 (m, 1H), 2.96 (q, J = 8.0 Hz, 1H), 1.09 (s, 9H).  δC (100MHz, 
CDCl3) 137.1, 137.0, 135.6, 133.1, 127.8, 116.9, 116.7, 73.5, 65.8, 51.0, 26.9, 19.3.  HRMS 
(ESI) m/z 389.1902 (C23H30O2SiNa
+ requires 389.1907).  IR (NaCl) ν 3468 (br), 3072, 3050, 
1635, 1472 cm-1. 
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1-(Trimethylsilyl)-4-vinylhex-5-en-1-yn-3-ol 
 
 
 
3-(Trimethylsilyl)-2-propynal (0.75 g, 5.94 mmol) and (E)-5-bromopenta-1,3-diene (1.05 g, 
7.13 mmol) were added to absolute ethanol (2.1 mL) and allowed to stir at room temperature.  
Indium powder (1.02 g, 8.91 mmol) was added slowly, so as not to increase the temperature of 
the reaction mixture, and then allowed to stir at room temperature for 72 h.  The reaction 
mixture was diluted with diethyl ether and then filtered through a plug of silica.  The solvent 
was removed by evaporation under reduced pressure.  The title compound was isolated by 
column chromatography (4:1, light petroleum: ethyl acetate, Rf = 0.6) yielding a pale yellow 
liquid (0.77 g, 3.98 mmol, 67%).  δH (400MHz, CDCl3) 5.99-5.83 (m, 2H), 5.28-5.18 (m, 4H), 
4.33 (dd, J = 5.6, 7.2 Hz, 1H), 3.07-3.02 (m, 1H), 2.10 (d, J = 7.2 Hz, 1H), 0.19 (s, 9H).  δC 
(100MHz, CDCl3) 136.1, 135.7, 118.7, 118.2, 104.6, 91.2, 65.3, 54.7, 0.0.  HRMS (ESI) m/z 
217.1020 (C11H18OSiNa
+ requires 217.1019).  IR (NaCl) ν 3429 (br), 3008, 2173, 1638 cm-1. 
  
146 
 
(E)-1-(Trimethylsilyl)octa-5,7-dien-1-yn-3-ol 
 
 
 
1-(Trimethylsilyl)-4-vinylhex-5-en-1-yn-3-ol (0.20 g, 1.03 mmol) in dichloromethane (2.1 
mL) was added to indium trifluoromethanesulfonate (58 mg, 10 mol %) and 3-(trimethylsilyl)-
2-propynal (13 mg, 10 mol %) and allowed to stir at room temperature for 24 h.  The reaction 
mixture was diluted with further dichloromethane and washed with distilled water.  The organic 
extracts were retained and the solvent removed by evaporation under reduced pressure.  The 
title compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf 
= 0.5) yielding a pale yellow liquid (0.11 g, 0.55 mmol, 53%).  δH (400MHz, CDCl3) 6.37 (td, 
J = 10.8, 16.8 Hz, 1H), 6.26-6.19 (m, 1H), 5.77 (td, J = 7.6, 14.8 Hz, 1H), 5.19 (dd, J = 0.8, 
16.8 Hz, 1H), 5.09 (dd, J = 1.2, 10.4 Hz, 1H), 4.43 (q, J = 6.0 Hz, 1H), 2.52 (t, J = 6.4 Hz, 2H), 
0.18 (s, 9H).  δC (100MHz, CDCl3) 137.0, 135.0, 128.5, 116.5, 105.9, 90.0, 62.2, 40.9, 0.1.  
HRMS (ESI) m/z 195.1200 (M+H) (C11H18OSi requires 195.1198 (M+H)).  IR (NaCl) ν 3400, 
2999, 2152, 1618 cm-1. 
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6.2.5 Methodology Development (chapter 4.3) 
General procedure for indium addition with (E)-5-bromopenta-1,3-diene[76] 
Aldehyde (1 mmol) and (E)-5-bromopenta-1,3-diene (1.2 mmol) were added to absolute 
ethanol (6 mmol) and allowed to stir at room temperature.  Indium powder (1.5 mmol) was 
added slowly, so as not to increase the temperature of the reaction mixture, and then allowed 
to stir at room temperature for 72 h.  The reaction mixture was diluted with diethyl ether and 
then filtered through a plug of silica.  The solvent was removed by evaporation under reduced 
pressure.  The title compound was isolated by column chromatography.  The following 
compounds were synthesised using this method. 
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 1-Cyclohexyl-2-vinylbut-3-en-1-ol 
 
 
 
Followed general procedure for indium addition with (E)-5-bromopenta-1,3-diene.  The title 
compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf = 
0.5) yielding a colourless liquid (0.137 g, 0.76 mmol, 76%).  δH (400MHz, CDCl3) 5.90-5.77 
(m, 2H), 5.20-5.07 (m, 2H), 3.30-3.25 (m, 1H), 2.95 (q, J = 7.2 Hz, 1H), 1,88-1.79 (m, 1H), 
1.78-1.69 (m, 2H), 1.68-1.57 (m, 2H), 1.48-1.37 (m, 1H), 1.29-1.00 (m, 5H).  δC (100MHz, 
CDCl3) 136.5, 135.3, 115.4, 114.2, 75.3, 49.7, 38.4, 27.9, 24.9, 24.5, 24.4 , 24.2.  HRMS (ESI) 
m/z 203.1406 (C12H20ONa
+ requires 203.1412).  IR (NaCl) ν 3435 (br), 3077, 1633 cm-1.  
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 1-Phenyl-2-vinylbut-3-en-1-ol 
 
 
 
Followed general procedure for indium addition with (E)-5-bromopenta-1,3-diene.  The title 
compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf = 
0.4) yielding a colourless liquid (0.157 g, 0.9 mmol, 90%).  δH (400MHz, CDCl3) 7.39-7.27 
(m, 5H), 5.88 (ddd, J = 8.2, 10.4, 17.2 Hz, 1H), 5.71 (ddd, J = 7.2, 10.4, 17.2 Hz, 1H), 5.19-
5.08 (m, 2H), 5.00-4.91 (m, 2H), 4.61 (d, J = 6.8 Hz, 1H), 3.13 (q, J = 7.2 Hz, 1H), 2.27 (br s, 
1H).  δC (100MHz, CDCl3) 140.8, 135.8, 135.7, 127.1, 126.9, 125.7, 117.4, 116.1, 75.2, 55.2.  
HRMS (ESI) m/z 173.0957 (M-H) (C12H14O requires 173.0961 (M-H)).  IR (NaCl) ν 3411 (br), 
3079, 3066, 1634, 1603 cm-1. 
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 6-Methyl-3-vinylhept-1-en-4-ol 
 
 
 
Followed general procedure for indium addition with (E)-5-bromopenta-1,3-diene.  The title 
compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf = 
0.4) yielding a colourless liquid (0.106 g, 0.69 mmol, 69%).  δH (400MHz, CDCl3) 5.89-5.79 
(m, 2H), 5.23-5.11 (m, 4H), 3.65 (dt, J = 4.4, 9.6 Hz, 1H), 2.79 (q, J = 7.6 Hz, 1H), 1.89-1.79 
(m, 1H), 1.65 (d, J = 4.4 Hz, 1H), 1.36-1.29 (m, 2H), 0.95 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.4 
Hz, 3H).  δC (100MHz, CDCl3) 137.6, 136.9, 117.6, 116.9, 71.2, 55.4, 43.4, 24.6, 23.8, 21.7.  
HRMS (ESI) m/z 154.1358 (C10H18O requires 154.1352).  IR (NaCl) ν 3368 (br), 3079, 1635 
cm-1. 
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 1-(4-Bromophenyl)-2-vinylbut-3-en-1-ol 
 
 
 
Followed general procedure for indium addition with (E)-5-bromopenta-1,3-diene.  The title 
compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf = 
0.4) yielding a colourless liquid (0.228 g, 0.9 mmol, 90%).  δH (400MHz, CDCl3) 7.44 (d, J = 
8.0 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H), 5.80 (ddd, J = 8.4, 10.8, 18.0 Hz, 1H), 5.64 (ddd, J = 7.2, 
10.8, 17.6 Hz, 1H), 5.25-5.13 (m, 2H), 5.07-4.97 (m, 2H), 4.54 (dd, J = 3.2, 7.2, Hz, 1H), 3.03 
(q, J = 7.6 Hz, 1H), 2.24 (d, J = 3.2 Hz, 1H).  δC (100MHz, CDCl3) 140.8, 136.4, 136.3, 131.2, 
128.6, 121.5, 118.8, 117.6, 75.5, 56.3.  HRMS (ESI) m/z 251.0068 (M-H) (C12H13O
79Br 
requires 251.0066 (M-H)).  IR (NaCl) ν 3420, 3079, 1635, 623 cm-1. 
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 1-(3-Bromophenyl)-2-vinylbut-3-en-1-ol 
 
 
 
Followed general procedure for indium addition with (E)-5-bromopenta-1,3-diene.  The title 
compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf = 
0.4) yielding a colourless liquid (0.180 g, 0.71 mmol, 71%).  δH (400MHz, CDCl3) 7.51-7.49 
(m, 1H), 7.44-7.40 (m, 1H), 7.26-7.19 (m, 2H), 5.83 (ddd, J = 8.0, 10.4, 17.2 Hz, 1H), 5.69 
(ddd, J = 7.2, 10.4, 17.6 Hz, 1H), 5.29-5.16 (m, 2H), 5.12-5.01 (m, 2H), 4.56 (d, J = 6.8 Hz, 
1H), 3.07 (q, J = 7.2 Hz, 1H), 2.40 (s, 1H).  δC (100MHz, CDCl3) 144.2, 136.3, 136.2, 130.7, 
129.9, 129.7, 125.6, 118.8, 117.6, 122.3, 75.5, 56.2.  HRMS (ESI) m/z 251.0058 (M-H) 
(C12H13O
79Br requires 251.0066 (M-H)).  IR (NaCl) ν 3400, 3084, 1637, 739 cm-1. 
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 1-(2-Bromophenyl)-2-vinylbut-3-en-1-ol 
 
 
 
Followed general procedure for indium addition with (E)-5-bromopenta-1,3-diene.  The title 
compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf = 
0.4) yielding a colourless liquid (0.225 g, 89 mmol, 89%).  δH (400MHz, CDCl3) 7.49 (dd, J = 
8.0, 15.6 Hz, 2H), 7.31 (t, J = 15.2 Hz, 1H), 7.11 (t, J = 7.6 Hz, 1H), 5.95-5.83 (m, 2H), 5.21-
5.01 (m, 5H), 3.20 (q, J = 6.8 Hz, 1H), 2.25 (s, 1H).  δC (100MHz, CDCl3) 141.1, 137.1, 135.6, 
132.7, 128.9, 129.6, 127.7, 122.6, 118.6, 117.0, 74.5, 54.4.  HRMS (ESI) m/z 251.0068 (M-H) 
(C12H13O
79Br requires 251.0066 (M-H)).  IR (NaCl) ν 3427, 3077, 1636, 619 cm-1. 
 
  
154 
 
 1-(Furan-3-yl)-2-vinylbut-3-en-1-ol 
 
 
 
Followed general procedure for indium addition with (E)-5-bromopenta-1,3-diene.  The title 
compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf = 
0.3) yielding a dark yellow liquid (0.08 g, 0.49 mmol, 49%).  δH (400MHz, CDCl3) 7.37 (d, J 
= 1.2 Hz, 2H), 6.38 (s, 1H), 5.80 (ddd, J = 8.0, 10.4, 17.2 Hz, 2H), 5.26-5.06 (m, 4H), 4.59 (dd, 
J = 4.4, 6.8 Hz, 1H), 3.08 (q, J = 6.8 Hz, 1H), 2.05 (d, J = 4.4 Hz, 1H).  δC (100MHz, CDCl3) 
143.2, 139.9, 136.7, 136.6, 126.5, 118.5, 117.5, 109.0, 69.0, 55.1.  HRMS (ESI) m/z 187.0728 
(C10H12O2Na
+ requires 187.0730).  IR (NaCl) ν 3413, 3079, 1614, 1161 cm-1. 
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 1-(4-Methoxyphenyl)-2-vinylbut-3-en-1-ol 
 
 
 
Followed general procedure for indium addition with (E)-5-bromopenta-1,3-diene.  The title 
compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf = 
0.3) yielding a dark yellow liquid (0.01 g, 0.05 mmol, 5%).  δH (400MHz, CDCl3) 7.22 (d, J = 
8.0 Hz, 2H), 6.86 (d, J = 7.6 Hz, 2H), 5.84 (dt, J = 9.2, 16.8 Hz, 1H), 5.64 (dt, J = 8.0, 16.8 Hz, 
1H), 5.21 (dd, J = 10.0, 16.4 Hz, 2H), 5.01 (t, J = 10.4 Hz, 2H), 4.52 (d, J = 7.2 Hz, 1H), 3.79 
(s, 3H), 3.07 (q, J = 7.6 Hz, 1H), 2.16 (s, 1H).  δC (100MHz, CDCl3) 159.1, 137.1, 136.8, 134.0, 
128.1, 118.3, 117.0, 113.6 (x2), 75.8, 56.3, 55.3.  HRMS (ESI) m/z 227.1037 (C13H16O2Na
+ 
requires 227.1043).  IR (NaCl) ν 3419 (br), 1634, 1219 cm-1. 
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 3-Vinylnon-1-en-4-ol 
 
 
 
Followed general procedure for indium addition with (E)-5-bromopenta-1,3-diene.  The title 
compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf = 
0.5) yielding a colourless liquid (0.114 g, 0.68 mmol, 68%).  δH (400MHz, CDCl3) 5.86-5.75 
(m, 2H), 5.21-5.07 (m, 4H), 3.57-3.49 (m, 1H), 2.78 (q, J = 8.0 Hz, 1H), 1.63 (d, J = 4.4 Hz, 
1H), 1.55-1.43 (m, 2H), 1.39-1.21 (m, 6H), 0.87 (t, J = 7.2 Hz, 3H).  δC (100MHz, CDCl3) 
137.7, 137.0, 117.6, 116.9, 73.3, 55.0, 34.2, 31.9, 25.5, 22.7, 14.1.  HRMS (ESI) m/z 191.1404 
(C11H20ONa
+ requires 191.1406).  IR (NaCl) ν 3390, 3078, 2999, 1635 cm-1. 
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General procedure for the rearrangement from branched to straight chain diene 
Branched chain diene (1 mmol) in dichloromethane (2 mL / mmol) was added to indium 
trifluoromethanesulfonate (10 mol %) and aldehyde (10 mol %) and allowed to stir at room 
temperature for 24 h.  The reaction mixture was diluted with further dichloromethane and 
washed with distilled water.  The organic extracts were retained and the solvent removed by 
evaporation under reduced pressure.  The title compound was isolated by column 
chromatography.  The following compounds were synthesised using this method. 
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 (E)-1-Cyclohexylhexa-3,5-dien-1-ol 
 
 
 
Followed general procedure for the rearrangement from branched to straight chain diene.  The 
title compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf 
= 0.4) yielding a colourless liquid (0.108 g, 0.60 mmol, 60%).  δH (400MHz, CDCl3) 6.31 (td, 
J = 10.4, 17.2 Hz, 1H), 6.18-6.08 (m, 1H), 5.70 (q, J = 8.0 Hz, 1H), 5.11 (d, J = 16.4 Hz, 2H), 
3.42-3.34 (m, 1H), 2.38-2.29 (m, 2H), 2.22-2.13 (m, 1H), 1.40-0.98 (m, 10H).  δC (100MHz, 
CDCl3) 136.9, 134.0, 131.3, 115.8, 75.3, 41.4, 29.9, 29.7, 26.6, 26.4, 26.3, 22.7.  HRMS (ESI) 
m/z 179.1429 (M-H) (C12H20O requires 179.1436 (M-H)).  IR (NaCl) ν 3457, 3088, 2928, 1650 
cm-1. 
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 (E)-1-Phenylhexa-3,5-dien-1-ol 
 
 
 
Followed general procedure for the rearrangement from branched to straight chain diene.  The 
title compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf 
= 0.3) yielding a colourless liquid (0.116 g, 0.67 mmol, 67%).  δH (400MHz, CDCl3) 7.42-7.29 
(m, 5H), 6.35 (td, J = 10.0, 16.8 Hz, 1H), 6.22 (dd, J = 10.4, 15.2 Hz, 1H), 5.71 (dt, J = 7.2, 
15.2 Hz, 1H), 5.18 (d, J = 16.4 Hz, 1H), 5.06 (d, J = 10.0 Hz, 1H), 4.80-4.74 (m, 1H), 2.60-
2.56 (m, 2H), 2.13 (d, J = 3.2 Hz, 1H).  δC (100MHz, CDCl3) 143.9, 136.8, 134.4, 130.1, 128.5, 
127.7, 125.8, 116.3, 73.7, 42.6.  HRMS (ESI) m/z 173.0958 (M-H) (C12H14O requires 173.0961 
(M-H)).  IR (NaCl) ν 3411, 3080, 3030, 1634, 1603 cm-1. 
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 (E)-1-(4-Bromophenyl)hexa-3,5-dien-1-ol 
 
 
 
Followed general procedure for the rearrangement from branched to straight chain diene.  The 
title compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf 
= 0.3) yielding a colourless liquid (0.180 g, 0.71 mmol, 71%).  δH (400MHz, CDCl3) 7.46 (d, 
J = 8.0 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 6.30 (td, J = 10.8, 16.8 Hz, 1H), 6.15 (dd, J = 10.4, 
15.6 Hz, 1H), 5.63 (dt, J = 8.0, 14.4 Hz, 1H), 5.15 (dd, J = 7.6, 16.8 Hz, 1H), 5.07-5.01 (m, 
1H), 4.74-4.66 (m, 1H), 2.55-2.43 (m, 2H), 2.00 (d, J = 3.2 Hz, 1H).  δC (100MHz, CDCl3) 
142.8. 136.6, 134.9, 131.6, 129.4, 127.6 (x2), 121.4, 116.6, 70.0, 42.7.  HRMS (ESI) m/z 
251.0059 (M-H) (C12H13O
79Br requires 251.0066 (M-H)).  IR (NaCl) ν 3419, 3079, 1635, 623 
cm-1. 
  
161 
 
 (E)-1-(3-Bromophenyl)hexa-3,5-dien-1-ol 
 
 
 
Followed general procedure for the rearrangement from branched to straight chain diene.  The 
title compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf 
= 0.3) yielding a colourless liquid (0.175 g, 0.69 mmol, 69%).  δH (400MHz, CDCl3) 7.57-7.54 
(m, 1H), 7.45-7.41 (m, 1H), 7.31-7.22 (m, 2H), 6.34 (td, J = 10.0, 16.8 Hz, 1H), 6.20 (dd, J = 
10.4, 15.2 Hz, 1H), 5.68 (dt, J = 7.6, 15.2 Hz, 1H), 5.19 (d, J = 16.8 Hz, 1H), 5.08 (d, J = 10.0 
Hz, 1H), 4.75-4.71 (m, 1H), 2.59-2.46 (m, 2H), 2.11 (d, J = 3.2 Hz, 1H).  δC (100MHz, CDCl3) 
146.2, 136.6, 134.9, 132.8, 130.6, 130.0, 129.4, 124.4, 122.6, 116.7, 72.9, 42.7.  HRMS (ESI) 
m/z 251.0059 (M-H) (C12H13O
79Br requires 251.0066 (M-H)).  IR (NaCl) ν 3391, 3084, 1637, 
704 cm-1. 
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 (E)-1-(2-Bromophenyl)hexa-3,5-dien-1-ol 
 
 
 
Followed general procedure for the rearrangement from branched to straight chain diene.  The 
title compound was isolated by column chromatography (4:1, light petroleum: ethyl acetate, Rf 
= 0.3) yielding a colourless liquid (0.182 g, 0.72 mmol, 72%).  δH (400MHz, CDCl3) 7.82 (d, 
J = 7.6 Hz, 1H), 7.64 (dd, J = 1.2, 8.0 Hz, 1H), 7.18-7.08 (m, 2H), 6.07 (d, J = 1.2 Hz, 1H), 
5.95-5.84 (m, 1H), 5.71 (dd, J = 5.6, 16 Hz, 1H), 5.29 (dd, J = 2.4, 5.6 Hz, 1H), 4.58 (dd, J = 
5.6, 10.8 Hz, 1H), 2.64-2.53 (m, 1H), 2.39-2.28 (m, 1H).  δC (100MHz, CDCl3) 142.7, 133.1, 
132.7, 132.6, 130.5, 128.5, 121.2, 100.6, 78.0, 77.2, 72.1, 40.6.  HRMS (ESI) m/z 251.0065 
(M-H) (C12H13O
79Br requires 251.0066 (M-H)).  IR (NaCl) ν 3428, 3077, 1636, 619 cm-1. 
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(E)-1-Phenylhexa-3,5-dien-1-yl acrylate[79] 
 
 
 
(E)-1-Phenylhexa-3,5-dien-1-ol (0.15 g, 0.87 mmol), acryloyl chloride (0.08 mL, 1.04 mmol), 
anhydrous triethylamine (0.15 mL, 1.1 mmol) and anhydrous dichloromethane (1.9 mL) were 
stirred under nitrogen at 0°C for 1 h, and then a further 2 h at room temperature.  The reaction 
mixture was then quenched with 5% HCl and the product extracted by diethyl ether.  The 
organic extracts were washed with brine, dried over magnesium sulfate, filtered and the solvent 
removed by evaporation under reduced pressure.  The title compound was isolated by column 
chromatography (4:1, light petroleum: ethyl acetate, Rf = 0.6) yielding a colourless oil (0.17g, 
0.74 mmol, 85%).  δH (500MHz, CDCl3) 7.40-7.36 (m, 4H), 7.35-7.30 (m, 1H), 6.45 (d, J = 
14.0 Hz, 1H), 6.29 (dt, J = 8.4, 14.0 Hz, 1H), 6.22-6.08 (m, 2H), 5.91 (t, J = 8.0 Hz, 1H), 5.86 
(d, J = 8.4 Hz, 1H), 5.60 (dt, J = 6.0, 12.0 Hz, 1H), 5.13 (d, J = 13.6 Hz, 1H), 5.02 (d, J = 8.0 
Hz, 1H), 2.79-2.63 (m, 2H).  δC (125MHz, CDCl3) 165.4, 139.9, 136.7, 134.2, 130.9, 128.8, 
128.6, 128.5, 128.0, 126.5, 116.2, 75.5, 39.6.  HRMS (ESI) m/z 227.1061 (M-H) (C15H16O2 
requires 227.1067 (M-H)).  IR (NaCl) ν 1735, 1678, 1240 cm-1. 
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3-Phenyl-3,4,4a,7,8,8a-hexahydro-1H-isochromen-1-one[80] 
 
 
 
A suspension of (E)-1-Phenylhexa-3,5-dien-1-yl acrylate (24 mg, 0.11 mmol) in 1-ethyl-3-
methylimidazolium tetrafluoroborate (1.47 mL) was warmed to 100°C and stirred for 6 h.  The 
reaction mixture was then cooled and the produced extracted by diethyl ether.  The solvent was 
removed by evaporation under reduced pressure and the title compound isolated by column 
chromatography (4:1, hexane: ethyl acetate, Rf = 0.3) yielding a colourless oil (22 mg, 0.096 
mmol, 87%).  δH (400MHz, CDCl3) 7.39-7.29 (m, 5H), 5.82-5.77 (m, 1H), 5.60-5.54 (m, 1H), 
5.30 (dd, J = 2.4, 11.6 Hz, 1H), 2.93-2.81 (m, 2H), 2.29-2.19 (m, 2H), 2.16-2.05 (m, 1H), 2.04-
1.92 (m, 2H), 1.70 (dt, J = 11.6, 14.4 Hz, 1H).  δC (100MHz, CDCl3) 174.4, 139.5, 128.7, 128.4, 
128.0, 127.9, 125.9, 80.4, 38.4, 36.5, 31.9, 23.6, 22.9.  HRMS (ESI) m/z 251.1037 
(C15H16O2Na
+ requires 251.1043).  IR (NaCl) ν 1734, 1679, 1245 cm-1.  (See Appendix 8.1 for 
nOe NMR spectra). 
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8.0 Appendix 
8.1 Determination of the configuration of 236 (Scheme 83) 
NMR spectroscopic data, including nOe spectroscopy, was used to determine the structure of 
IMDA product 238, as discussed in Scheme 83, page 111.  The possible configurations are 
shown in Figure 37.  Gaussian calculations show that cis-decalin phenyl-equatorial 
configuration is the lowest energy conformer shown in Figure 37, and cis-decalin phenyl-axial 
twist is the highest energy conformer. 
 
 
Figure 37.  Possible configurations of IMDA product 238. 
 
The conformer shown in Figure 38 is numbered to enable discussion of the nOe spectroscopic 
data (with the spectra numbered accordingly).  The same numbering apply to all conformers.  
The conformer labelled cis-decalin phenyl-axial in Figure 37 can be disregarded on the basis 
of the splitting pattern of HA on the 1H NMR spectrum being a clear doublet of doublets.  If 
cis-decalin phenyl-axial was the correct configuration, HA would be seen as a triplet as both H1 
171 
 
protons would be in a chemically equivalent environment (as can be seen in Figure 37).  All 
other conformers would show HA as the doublet of doublets seen experimentally. 
 
 
Figure 38. IMDA product 238 labelled for referral to spectroscopic data. 
 
The experimental spectral data shows clear nOe coupling through space of HA (Figure 38) to 
H2 and H7.  With respect to HA, trans-decalin phenyl-axial would only show nOe coupling 
through space with H7, trans-decalin phenyl-equatorial would only show nOe coupling through 
space with H2, cis-decalin phenyl-equatorial would show nOe coupling through space to H2 
and H7, and both cis-decalin phenyl-axial twist and cis-decalin phenyl-axial (already ruled out 
due to splitting patterns) wouldn’t show nOe coupling through space to either H2 or H7.  Only 
cis-decalin phenyl-equatorial has HA on the same face as both H2 and H7 and would allow 
coupling through space to both of them.  To support this, there is also experimental nOe 
coupling through space between H1 and H6 which is also characteristic of cis-decalin phenyl-
equatorial.  The experimental spectroscopic data is therefore in agreement with the Gaussian 
calculations, suggesting that the configuration of IMDA product 238 is cis-decalin phenyl-
equatorial as shown in Figure 39. 
 
 
Figure 39.  The configuration of IMDA product 238 in agreement with experimental spectroscopic data. 
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